| Drug |
carboplatin |
355 |
2010 |
| Drug |
paclitaxel |
244 |
2010 |
| Drug |
cisplatin |
233 |
2014 |
| Drug |
pemetrexed |
210 |
2014 |
| Drug |
docetaxel |
192 |
2014 |
| placebo |
placebo |
158 |
2010 |
| Drug |
gemcitabine |
137 |
2014 |
| Drug |
pembrolizumab |
133 |
2015 |
| Drug |
erlotinib |
114 |
2011 |
| Radiation |
radiotherapy |
105 |
2016 |
| Other |
laboratory biomarker analysis |
102 |
2014 |
| Drug |
bevacizumab |
98 |
2017 |
| Drug |
nivolumab |
91 |
2015 |
| Drug |
gefitinib |
66 |
2011 |
| Drug |
durvalumab |
54 |
2018 |
| Drug |
cetuximab |
48 |
2009 |
| Drug |
gemcitabine hydrochloride |
44 |
2017 |
| Drug |
vinorelbine |
40 |
2010 |
| Drug |
osimertinib |
36 |
2018 |
| Drug |
atezolizumab |
35 |
2016 |
| Drug |
erlotinib hydrochloride |
34 |
2017 |
| Drug |
chemotherapy |
33 |
2017 |
| Biological |
ipilimumab |
33 |
2014 |
| Drug |
nab-paclitaxel |
31 |
2014 |
| Other |
quality-of-life assessment |
31 |
2014 |
| Other |
pharmacological study |
29 |
2013 |
| Drug |
pemetrexed disodium |
26 |
2017 |
| Radiation |
stereotactic body radiation therapy |
24 |
2010 |
| Drug |
afatinib |
21 |
2013 |
| Drug |
etoposide |
20 |
2014 |
| Other |
questionnaire administration |
20 |
2014 |
| Drug |
crizotinib |
19 |
2016 |
| Drug |
erlotinib [tarceva] |
19 |
2010 |
| Drug |
anlotinib |
16 |
2018 |
| Drug |
ramucirumab |
16 |
2010 |
| Drug |
celecoxib |
15 |
2007 |
| Radiation |
radiation |
14 |
2018 |
| Radiation |
sbrt |
14 |
2018 |
| Procedure |
surgery |
14 |
2009 |
| Procedure |
therapeutic conventional surgery |
14 |
2018 |
| Drug |
tremelimumab |
14 |
2018 |
| Drug |
vinorelbine tartrate |
14 |
2011 |
| Drug |
alectinib |
13 |
2016 |
| Drug |
avelumab |
13 |
2017 |
| Procedure |
conventional surgery |
13 |
2018 |
| Drug |
bortezomib |
12 |
2008 |
| Drug |
icotinib |
12 |
2017 |
| Drug |
necitumumab |
12 |
2019 |
| Drug |
selumetinib |
12 |
2018 |
| Drug |
sintilimab |
12 |
2018 |
| Drug |
brigatinib |
11 |
2018 |
| Drug |
cyclophosphamide |
11 |
2009 |
| Drug |
vorinostat |
11 |
2009 |
| Other |
best supportive care |
10 |
2011 |
| Drug |
bibw 2992 |
10 |
2009 |
| Radiation |
3-dimensional conformal radiation therapy |
9 |
2014 |
| Drug |
azd9291 |
9 |
2016 |
| Drug |
bevacizumab [avastin] |
9 |
2009 |
| Drug |
olaparib |
9 |
2016 |
| Radiation |
stereotactic body radiation therapy (sbrt) |
9 |
2018 |
| Drug |
sunitinib |
9 |
2008 |
| Drug |
trametinib |
9 |
2017 |
| Drug |
pazopanib |
8 |
2009 |
| Drug |
pemetrexed/cisplatin |
8 |
2010 |
| Drug |
sorafenib |
8 |
2009 |
| Procedure |
adjuvant therapy |
7 |
2006 |
| Drug |
azd6244 |
7 |
2010 |
| Drug |
ceritinib |
7 |
2015 |
| Other |
ct-scan |
7 |
2009 |
| Drug |
everolimus |
7 |
2016 |
| Drug |
gemcitabine/carboplatin |
7 |
2010 |
| Radiation |
intensity-modulated radiation therapy |
7 |
2014 |
| Drug |
kg |
7 |
2019 |
| Drug |
m^2 |
7 |
2016 |
| Procedure |
neoadjuvant therapy |
7 |
2019 |
| Drug |
oxaliplatin |
7 |
2019 |
| Drug |
atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody |
6 |
2017 |
| Drug |
bibf 1120 |
6 |
2011 |
| Drug |
cabozantinib |
6 |
2018 |
| Drug |
cediranib maleate |
6 |
2010 |
| Drug |
concurrent chemotherapy |
6 |
2019 |
| Drug |
dexamethasone |
6 |
2010 |
| Drug |
entinostat |
6 |
2016 |
| Drug |
gemcitabine/cisplatin |
6 |
2010 |
| Other |
immunohistochemistry staining method |
6 |
2008 |
| Drug |
irinotecan hydrochloride |
6 |
2007 |
| Drug |
ldk378 |
6 |
2014 |
| Drug |
medi4736 |
6 |
2014 |
| Drug |
nintedanib |
6 |
2014 |
| Other |
pet |
6 |
2005 |
| Procedure |
positron emission tomography |
6 |
2014 |
| Drug |
standard care |
6 |
2019 |
| Drug |
veliparib |
6 |
2016 |
| Drug |
abemaciclib |
5 |
2015 |
| Drug |
anamorelin hcl |
5 |
2018 |
| Drug |
anlotinib hydrochloride |
5 |
2019 |
| Drug |
apatinib |
5 |
2017 |
| Drug |
arq 197 |
5 |
2012 |
| Drug |
auy922 |
5 |
2013 |
| Drug |
bavituximab |
5 |
2010 |
| Drug |
canakinumab |
5 |
2019 |
| Drug |
cobimetinib |
5 |
2018 |
| Other |
educational intervention |
5 |
2012 |
| Drug |
erlotinib hcl |
5 |
2009 |
| Genetic |
gene expression analysis |
5 |
2007 |
| Radiation |
hypofractionated radiation therapy |
5 |
2014 |
| Drug |
inc280 |
5 |
2014 |
| Drug |
irinotecan |
5 |
2009 |
| Drug |
lenvatinib |
5 |
2019 |
| Drug |
lorlatinib |
5 |
2018 |
| Drug |
m2 |
5 |
2012 |
| Drug |
mk-3475 |
5 |
2014 |
| Drug |
oleclumab |
5 |
2016 |
| Drug |
paclitaxel / carboplatin |
5 |
2010 |
| Drug |
palbociclib |
5 |
2017 |
| Biological |
pembrolizumab 200 mg |
5 |
2019 |
| Drug |
pf-00299804 |
5 |
2010 |
| Genetic |
protein expression analysis |
5 |
2007 |
| Radiation |
split-course radiotherapy |
5 |
2019 |
| Drug |
temozolomide |
5 |
2000 |
| Radiation |
thoracic radiotherapy |
5 |
2020 |
| Biological |
trastuzumab |
5 |
2017 |
| Drug |
vandetanib |
5 |
2014 |
| Drug |
ac0010 |
4 |
2016 |
| Drug |
alimta |
4 |
2007 |
| Drug |
anlotinib/docetaxel |
4 |
2018 |
| Procedure |
az7550 |
4 |
2014 |
| Drug |
bi 754091 |
4 |
2018 |
| Drug |
binimetinib |
4 |
2019 |
| Drug |
bkm120 |
4 |
2014 |
| Drug |
cabozantinib s-malate |
4 |
2018 |
| Drug |
camrelizumab |
4 |
2019 |
| Drug |
cc-486 |
4 |
2014 |
| Biological |
cixutumumab |
4 |
2010 |
| Other |
clinical observation |
4 |
2014 |
| Procedure |
computed tomography |
4 |
2014 |
| Drug |
dasatinib |
4 |
2016 |
| Drug |
docetaxel/cisplatin |
4 |
2010 |
| Drug |
egf816 |
4 |
2014 |
| Drug |
enzastaurin |
4 |
2007 |
| Drug |
erlotinib (tarceva) |
4 |
2007 |
| Behavioral |
exercise |
4 |
2017 |
| Drug |
fludarabine |
4 |
2019 |
| Radiation |
fludeoxyglucose f 18 |
4 |
2009 |
| Dietary Supplement |
folic acid |
4 |
2010 |
| Drug |
fruquintinib |
4 |
2015 |
| Drug |
gemcitabine / carboplatin |
4 |
2015 |
| Drug |
gemcitabine / cisplatin |
4 |
2015 |
| Drug |
imatinib mesylate |
4 |
2010 |
| Other |
immunoenzyme technique |
4 |
2006 |
| Drug |
mpdl3280a |
4 |
2014 |
| Other |
observation |
4 |
2020 |
| Drug |
paclitaxel albumin-stabilized nanoparticle formulation |
4 |
2012 |
| Drug |
pdr001 |
4 |
2016 |
| Drug |
pemetrexed / carboplatin |
4 |
2015 |
| Drug |
pemetrexed / cisplatin |
4 |
2015 |
| Drug |
pemetrexed 500 mg |
4 |
2013 |
| Drug |
pemetrexed/carboplatin |
4 |
2019 |
| Drug |
pertuzumab |
4 |
2015 |
| Other |
pet/ct |
4 |
2018 |
| Drug |
pf-02341066 |
4 |
2007 |
| Procedure |
pharmacokinetic sampling - az5140 |
4 |
2014 |
| Procedure |
pharmacokinetic sampling - az5140/az7550 |
4 |
2014 |
| Procedure |
pharmacokinetic sampling - azd9291 |
4 |
2014 |
| Radiation |
proton beam radiation therapy |
4 |
2014 |
| Behavioral |
questionnaire |
4 |
2011 |
| Drug |
ribociclib |
4 |
2014 |
| Drug |
s-1 |
4 |
2011 |
| Drug |
single low dose cyclophosphamide |
4 |
2009 |
| Radiation |
stereotactic body radiotherapy |
4 |
2017 |
| Radiation |
stereotactic body radiotherapy (sbrt) |
4 |
2019 |
| Drug |
tak-788 |
4 |
2019 |
| Drug |
tarceva |
4 |
2009 |
| Biological |
tecemotide (l-blp25) |
4 |
2009 |
| Drug |
temsirolimus |
4 |
2010 |
| Drug |
tipifarnib |
4 |
2018 |
| Drug |
vinorelbine ditartrate |
4 |
2010 |
| Dietary Supplement |
vitamin b12 |
4 |
2010 |
| Drug |
vitamin c |
4 |
2016 |
| Drug |
NA |
3 |
2018 |
| Drug |
40 mg |
3 |
2018 |
| Drug |
abi-007 |
3 |
2011 |
| Drug |
alflutinib |
3 |
2018 |
| Drug |
amifostine trihydrate |
3 |
1999 |
| Drug |
arq 197/erlotinib |
3 |
2010 |
| Drug |
axitinib |
3 |
2017 |
| Drug |
azd3759 |
3 |
2017 |
| Drug |
azd4547 |
3 |
2013 |
| Drug |
azd6738 |
3 |
2019 |
| Drug |
azd9291 80 mg |
3 |
2015 |
| Drug |
azd9291 tablet dosing |
3 |
2014 |
| Other |
best available therapy |
3 |
2017 |
| Drug |
bexarotene |
3 |
2006 |
| Procedure |
biopsy |
3 |
2018 |
| Other |
blood sample |
3 |
2018 |
| Drug |
capecitabine |
3 |
2013 |
| Drug |
carboplatin/paclitaxel |
3 |
2018 |
| Drug |
cisplatin 75 mg |
3 |
2013 |
| Drug |
cisplatin 75 mg/m^2 |
3 |
2013 |
| Drug |
cp-751,871 |
3 |
2005 |
| Drug |
cs-7017 |
3 |
2010 |
| Drug |
dacomitinib |
3 |
2011 |
| Drug |
danvatirsen |
3 |
2016 |
| Drug |
darbepoetin alfa |
3 |
2006 |
| Drug |
durvalumab (medi4736) |
3 |
2019 |
| Procedure |
ebus-tbna |
3 |
2009 |
| Drug |
endostar |
3 |
2016 |
| Drug |
epacadostat |
3 |
2017 |
| Drug |
exemestane |
3 |
2016 |
| Drug |
exisulind |
3 |
2004 |
| Radiation |
fdg-pet |
3 |
2015 |
| Other |
flow cytometry |
3 |
2006 |
| Drug |
fludeoxyglucose f-18 |
3 |
2018 |
| Drug |
gefitinib 250 mg |
3 |
2018 |
| Drug |
gm-csf |
3 |
2013 |
| Radiation |
image guided radiation therapy |
3 |
2013 |
| Drug |
ipi |
3 |
2018 |
| Drug |
itraconazole |
3 |
2015 |
| Drug |
m7824 |
3 |
2018 |
| Other |
medical chart review |
3 |
2012 |
| Drug |
metformin |
3 |
2017 |
| Drug |
metformin hydrochloride |
3 |
2014 |
| Drug |
mm-121 |
3 |
2009 |
| Drug |
motexafin gadolinium |
3 |
2005 |
| Genetic |
mutation analysis |
3 |
2010 |
| Drug |
nimotuzumab |
3 |
2018 |
| Drug |
paclitaxel 200 mg |
3 |
2013 |
| Drug |
paclitaxel 200 mg/m^2 |
3 |
2013 |
| Drug |
paclitaxel/carboplatin |
3 |
2010 |
| Drug |
panitumumab |
3 |
2009 |
| Biological |
pegfilgrastim |
3 |
2012 |
| Drug |
pemetrexed 500 mg/m^2 |
3 |
2013 |
| Drug |
placebo/docetaxel |
3 |
2011 |
| Drug |
platinum |
3 |
2013 |
| Drug |
porfimer sodium |
3 |
2016 |
| Drug |
poziotinib |
3 |
2017 |
| Drug |
rad001 |
3 |
2007 |
| Drug |
saline solution |
3 |
2019 |
| Biological |
shr-1210 |
3 |
2018 |
| Drug |
sirolimus |
3 |
2012 |
| Drug |
sitravatinib |
3 |
2019 |
| Drug |
sorafenib (nexavar, bay43-9006) |
3 |
2009 |
| Radiation |
stereotactic radiosurgery |
3 |
2016 |
| Radiation |
stereotactic radiotherapy |
3 |
2009 |
| Drug |
suramin |
3 |
2012 |
| Drug |
tcm |
3 |
2011 |
| Drug |
tepotinib |
3 |
2019 |
| Drug |
thalidomide |
3 |
2017 |
| Drug |
tirapazamine |
3 |
2001 |
| Drug |
topotecan |
3 |
2015 |
| Drug |
trastuzumab emtansine |
3 |
2014 |
| Drug |
triapine |
3 |
2004 |
| Drug |
tyrosine kinase inhibitor |
3 |
2016 |
| Drug |
vinblastine sulfate |
3 |
2017 |
| Drug |
zd1839 |
3 |
2005 |
| Drug |
zd6474 |
3 |
2003 |
| Drug |
zoledronic acid |
3 |
2013 |
| Radiation |
18 f fluorodeoxyglucose |
2 |
2009 |
| Drug |
ab928 |
2 |
2020 |
| Drug |
abr-217620 |
2 |
2005 |
| Drug |
abt-751 |
2 |
2003 |
| Drug |
abx-egf |
2 |
2005 |
| Other |
adjuvant |
2 |
2017 |
| Biological |
adv |
2 |
2016 |
| Biological |
adv/hsv-tk |
2 |
2016 |
| Drug |
afatinib (bibw 2992) |
2 |
2009 |
| Drug |
afatinib dimaleate |
2 |
2015 |
| Biological |
ak105 |
2 |
2019 |
| Biological |
aldesleukin |
2 |
2014 |
| Biological |
alt-803 |
2 |
2015 |
| Drug |
anamorelin hydrochloride |
2 |
2018 |
| Drug |
anlotinib/pemetrexed |
2 |
2018 |
| Biological |
antigen-specific dth |
2 |
2019 |
| Drug |
antroquinonol |
2 |
2014 |
| Drug |
aprepitant |
2 |
2015 |
| Drug |
apricoxib |
2 |
2008 |
| Drug |
apx005m |
2 |
2018 |
| Drug |
atezolizumab (mpdl3280a) [tecentriq], an engineered anti-pdl1 antibody |
2 |
2015 |
| Biological |
avastin |
2 |
2014 |
| Drug |
avastin (bevacizumab) |
2 |
2016 |
| Drug |
axl1717 |
2 |
2011 |
| Drug |
azacitidine |
2 |
2013 |
| Drug |
azd4635 |
2 |
2016 |
| Drug |
azd5363 |
2 |
2016 |
| Drug |
azd9150 |
2 |
2018 |
| Drug |
bi 2536 |
2 |
2014 |
| Drug |
bi 754111 |
2 |
2018 |
| Drug |
bms-690514 |
2 |
2010 |
| Drug |
bms-986205 |
2 |
2016 |
| Drug |
bpi-7711 |
2 |
2019 |
| Drug |
capmatinib |
2 |
2019 |
| Drug |
carboplatin auc6 |
2 |
2018 |
| Drug |
carboplatin) |
2 |
2009 |
| Drug |
carboplatin/gemcitabine |
2 |
2007 |
| Biological |
cemiplimab |
2 |
2017 |
| Drug |
chemo |
2 |
2018 |
| Drug |
chidamide |
2 |
2018 |
| Biological |
cik cell |
2 |
2012 |
| Drug |
cis-platinum |
2 |
2012 |
| Drug |
cisplatin injection |
2 |
2020 |
| Drug |
cisplatin/carboplatin |
2 |
2011 |
| Device |
computed tomography perfusion imaging |
2 |
2017 |
| Biological |
control dth |
2 |
2019 |
| Other |
counseling intervention |
2 |
2011 |
| Drug |
cpt-11 |
2 |
2006 |
| Biological |
cs1001 monoclonal antibody |
2 |
2018 |
| placebo |
cs1001 placebo |
2 |
2018 |
| Other |
cytology specimen collection procedure |
2 |
2014 |
| Drug |
d-0316 |
2 |
2019 |
| Drug |
dabrafenib |
2 |
2011 |
| Drug |
dacomitinib (pf-00299804) |
2 |
2011 |
| Drug |
dalotuzumab |
2 |
2008 |
| Drug |
day |
2 |
2012 |
| Drug |
decitabine |
2 |
2004 |
| Biological |
dendritic cell immunotherapy |
2 |
2019 |
| Drug |
denosumab |
2 |
2014 |
| Drug |
dexamethasone 4 mg |
2 |
2019 |
| Other |
diagnostic laboratory biomarker analysis |
2 |
2011 |
| Drug |
dnib0600a |
2 |
2013 |
| Drug |
docetaxel (taxotereâ®) |
2 |
2007 |
| Drug |
docetaxel 75 mg |
2 |
2016 |
| Drug |
docetaxel/carboplatin |
2 |
2016 |
| Drug |
docetaxel/pemetrexed |
2 |
2008 |
| Biological |
dribble vaccine |
2 |
2009 |
| Drug |
ds-1205c |
2 |
2018 |
| Combination Product |
durvalumab / monalizumab |
2 |
2018 |
| Combination Product |
durvalumab / oleclumab |
2 |
2018 |
| Drug |
ec20 |
2 |
2012 |
| Drug |
ef5 |
2 |
2014 |
| Drug |
egfr |
2 |
2017 |
| Biological |
enoblituzumab |
2 |
2015 |
| Drug |
ensartinib |
2 |
2016 |
| Drug |
entrectinib |
2 |
2015 |
| Drug |
eribulin mesylate |
2 |
2006 |
| Radiation |
external beam radiation therapy |
2 |
2012 |
| Device |
flt-pet |
2 |
2016 |
| Dietary Supplement |
folic acid 350-1000 î¼g |
2 |
2019 |
| Drug |
gdc-0941 |
2 |
2009 |
| Drug |
gefitinib (iressa) |
2 |
2009 |
| Drug |
glumetinib |
2 |
2019 |
| Drug |
gtx-024 |
2 |
2011 |
| Biological |
hla-a*2402restricted urlc10, cdca1, |
2 |
2013 |
| Drug |
hm61713 |
2 |
2012 |
| Drug |
hsp90 inhibitor auy922 |
2 |
2013 |
| Biological |
hsv-tk |
2 |
2016 |
| Drug |
hydroxychloroquine |
2 |
2009 |
| Radiation |
hypofractionated radiotherapy |
2 |
2009 |
| Drug |
ibrutinib |
2 |
2014 |
| Drug |
ifosfamide |
2 |
2005 |
| Device |
ima_detect |
2 |
2018 |
| Radiation |
image-guided radiation therapy |
2 |
2018 |
| Drug |
iressa |
2 |
2005 |
| Biological |
isis 3521 |
2 |
1999 |
| Drug |
itacitinib |
2 |
2018 |
| Drug |
ixabepilone |
2 |
2009 |
| Drug |
ixabepilone, 32 mg |
2 |
2008 |
| Drug |
jnj-61186372 |
2 |
2019 |
| Biological |
kn046 |
2 |
2019 |
| Drug |
l-dos47 |
2 |
2013 |
| Drug |
lapatinib |
2 |
2011 |
| Drug |
lazertinib |
2 |
2019 |
| Procedure |
lobectomy |
2 |
2017 |
| Procedure |
local consolidation therapy |
2 |
2018 |
| Drug |
lxh254 |
2 |
2017 |
| Drug |
ly2603618 |
2 |
2009 |
| Biological |
ly2875358 |
2 |
2012 |
| Drug |
ly900003 |
2 |
2002 |
| Drug |
methylprednisolone |
2 |
2013 |
| Drug |
midazolam |
2 |
2014 |
| Drug |
mifepristone |
2 |
2015 |
| Drug |
min |
2 |
2013 |
| Drug |
minocycline |
2 |
2011 |
| Drug |
mk-2206 |
2 |
2011 |
| Drug |
ml intravenous solution |
2 |
2019 |
| Combination Product |
monalizumab |
2 |
2018 |
| Drug |
nab paclitaxel |
2 |
2020 |
| Procedure |
needle biopsy |
2 |
2010 |
| Biological |
neo-pv-01 |
2 |
2017 |
| Drug |
niraparib |
2 |
2017 |
| Drug |
nivolumab 10 mg |
2 |
2019 |
| Drug |
nivolumab 10 mg/ml intravenous solution |
2 |
2019 |
| Biological |
nk immunotherapy |
2 |
2016 |
| Device |
novottf-100l |
2 |
2008 |
| Drug |
onartuzumab |
2 |
2013 |
| Drug |
ono-4538 |
2 |
2015 |
| Drug |
oral vinorelbine |
2 |
2008 |
| Drug |
osi-906 |
2 |
2010 |
| Drug |
osimertinib mesylate tablets |
2 |
2018 |
| Drug |
paclitaxel injection |
2 |
2020 |
| Drug |
patupilone |
2 |
2005 |
| Biological |
pembrolizumab 2 mg |
2 |
2016 |
| Biological |
pembrolizumab 2 mg/kg |
2 |
2016 |
| Drug |
pemetrexed (alimta) |
2 |
2009 |
| Device |
pet scan imaging |
2 |
2015 |
| Drug |
pf-06463922 |
2 |
2013 |
| Drug |
pf-3512676 |
2 |
2002 |
| Other |
pharmacogenomic studies |
2 |
2012 |
| Other |
pharmacokinetic study |
2 |
2018 |
| Drug |
photodynamic therapy |
2 |
2013 |
| Radiation |
photon beam radiation therapy |
2 |
2012 |
| Radiation |
photon therapy |
2 |
2009 |
| Drug |
pi-88 |
2 |
2005 |
| placebo |
placebo azd9291 80 mg |
2 |
2015 |
| placebo |
placebo capsule |
2 |
2013 |
| placebo |
placebo for olaparib |
2 |
2020 |
| placebo |
placebo gefitinib 250 mg |
2 |
2018 |
| Drug |
platinum-based chemotherapy |
2 |
2017 |
| Drug |
plb1001 |
2 |
2020 |
| Drug |
ponatinib |
2 |
2013 |
| Drug |
pralatrexate |
2 |
2000 |
| Radiation |
proton radiotherapy |
2 |
2007 |
| Radiation |
proton therapy |
2 |
2009 |
| Procedure |
radiofrequency ablation |
2 |
2007 |
| Radiation |
radiolabeled (99tc) ec-dg (ethylenedicysteine-deoxyglucose) |
2 |
2009 |
| Biological |
ras peptide cancer vaccine |
2 |
2007 |
| Biological |
recombinant ephb4-hsa fusion protein |
2 |
2017 |
| Drug |
recombinant human endostatin |
2 |
2010 |
| Drug |
regn2810 |
2 |
2018 |
| Drug |
regn2810/chemo/ipi |
2 |
2018 |
| Drug |
regorafenib |
2 |
2018 |
| Other |
rehabilitation education |
2 |
2017 |
| Behavioral |
rehabilitation training |
2 |
2017 |
| Drug |
retifanlimab |
2 |
2018 |
| Biological |
romiplostim |
2 |
2019 |
| Radiation |
sabr |
2 |
2018 |
| placebo |
saline placebo for pembrolizumab |
2 |
2016 |
| Drug |
sar408701 |
2 |
2019 |
| Drug |
savolitinib |
2 |
2019 |
| Drug |
selinexor |
2 |
2017 |
| Drug |
selpercatinib |
2 |
2020 |
| Drug |
simvastatin |
2 |
2014 |
| Procedure |
single photon emission computed tomography |
2 |
2016 |
| Biological |
sintilimab injection |
2 |
2020 |
| Drug |
sndx-275 |
2 |
2008 |
| Drug |
sorafenib tosylate |
2 |
2007 |
| Drug |
spartalizumab |
2 |
2019 |
| Drug |
standard chemotherapy |
2 |
2013 |
| Procedure |
standard follow-up care |
2 |
2013 |
| Procedure |
stereotactic ablative radiotherapy (sabr) |
2 |
2015 |
| Drug |
sunitinib malate |
2 |
2008 |
| Other |
supportive care |
2 |
2016 |
| Procedure |
surgical resection |
2 |
2019 |
| Drug |
tagrisso |
2 |
2016 |
| Drug |
talactoferrin |
2 |
2009 |
| Drug |
tarceva (erlotinib hcl) |
2 |
2004 |
| Drug |
tarceva (trademark) (erlotinib hcl, osi-774) |
2 |
2004 |
| Drug |
taxol |
2 |
2005 |
| Drug |
taxotere |
2 |
2004 |
| Biological |
tg4010 |
2 |
2017 |
| Procedure |
therapeutic thoracoscopy |
2 |
1999 |
| Radiation |
thoracic irradiation |
2 |
2020 |
| Radiation |
thoracic radiation therapy (trt) |
2 |
2018 |
| Procedure |
thoracic surgical procedure |
2 |
2017 |
| Drug |
tislelizumab |
2 |
2020 |
| Drug |
tisotumab vedotin |
2 |
2017 |
| Drug |
tki |
2 |
2018 |
| Drug |
tlk286 |
2 |
2004 |
| Drug |
topotecan hydrochloride |
2 |
2006 |
| Biological |
toripalimab |
2 |
2019 |
| Drug |
tq-b3139 |
2 |
2019 |
| Drug |
trastuzumab deruxtecan (ds-8201a) |
2 |
2019 |
| Drug |
valacyclovir |
2 |
2016 |
| Biological |
vegfr2 |
2 |
2009 |
| Drug |
velcade |
2 |
2006 |
| Drug |
vemurafenib |
2 |
2017 |
| Drug |
vidaza |
2 |
2014 |
| Procedure |
video-assisted surgery |
2 |
1999 |
| Drug |
vinorelbine (navelbine) |
2 |
2008 |
| Drug |
vinorelbine/cisplatin |
2 |
2011 |
| Drug |
vistusertib |
2 |
2017 |
| Dietary Supplement |
vitamin b12 1000 î¼g |
2 |
2019 |
| Device |
voc analysis |
2 |
2018 |
| Radiation |
whole-brain radiotherapy |
2 |
2015 |
| Drug |
x-396 (ensartinib) |
2 |
2016 |
| Drug |
xl647 |
2 |
2007 |
| Drug |
ym155 |
2 |
2010 |
| Drug |
zimberelimab |
2 |
2020 |
| Drug |
[11c]osimertinib |
1 |
2018 |
| Drug |
[14c]pf00299804 |
1 |
2009 |
| Radiation |
[18f]fluoroglucose(fdg) |
1 |
2015 |
| Drug |
01 |
1 |
2002 |
| Drug |
1 year follow-up; |
1 |
2020 |
| Drug |
100 mg |
1 |
2014 |
| Drug |
100mg |
1 |
2014 |
| Drug |
160 mg |
1 |
2020 |
| Drug |
1650-g vaccine |
1 |
2008 |
| Drug |
18f-arag |
1 |
2019 |
| Drug |
18f-fdg |
1 |
2015 |
| Procedure |
18f-fdg-pet scan |
1 |
2014 |
| Drug |
18f-fludeoxyglucose (18f-fdg) |
1 |
2013 |
| Drug |
18f-fluoromisonidazole |
1 |
2012 |
| Drug |
18f-fmiso |
1 |
2013 |
| Drug |
18f-fpprgd2 |
1 |
2013 |
| Drug |
18f-fspg |
1 |
2015 |
| Other |
18f-pd-l1 |
1 |
2018 |
| Drug |
1st line chemotherapy |
1 |
2006 |
| Other |
2-deoxy-2-[18f]fluoro-d-glucose (fdg) |
1 |
2007 |
| Radiation |
2.5 gy |
1 |
2018 |
| Radiation |
2.5 gy/fraction |
1 |
2018 |
| Drug |
2503 |
1 |
2017 |
| Procedure |
2d vats lobectomy |
1 |
2019 |
| Other |
3’-deoxy-3’-[18f]fluorothymidine (flt) |
1 |
2007 |
| Radiation |
3-d crt) |
1 |
2014 |
| Radiation |
3-dimensional conformal radiation therapy (3d-crt) |
1 |
2017 |
| Radiation |
34 gy in a single fraction |
1 |
2013 |
| Diagnostic Test |
3d-ex |
1 |
2017 |
| Radiation |
3d conform radiotherapy |
1 |
2009 |
| Procedure |
3d vats lobectomy |
1 |
2019 |
| Diagnostic Test |
4-d ct scan |
1 |
2017 |
| Drug |
40mg |
1 |
2018 |
| Other |
4d-ct scan |
1 |
2012 |
| Device |
4d pet-ct |
1 |
2011 |
| Drug |
5-flourouracil |
1 |
2018 |
| Drug |
5-fluorouracil) |
1 |
2013 |
| Radiation |
54gy 18gy |
1 |
2013 |
| Radiation |
54gy 18gy/fr. x 3 fractions |
1 |
2013 |
| Drug |
6-hydroxymethylacylfulvene |
1 |
1999 |
| Radiation |
60 gy rt |
1 |
2007 |
| Radiation |
60gy (12 x 5 fr.s) |
1 |
2013 |
| Radiation |
60gy (7.5gy x 8fr.) |
1 |
2013 |
| Other |
68ga-nota-ae105 pet |
1 |
2016 |
| Other |
68ga-nota-ae105 pet/ct |
1 |
2016 |
| Drug |
7-hydroxystaurosporine |
1 |
2002 |
| Radiation |
70 gy in 20 fractions over 4 weeks |
1 |
2015 |
| Radiation |
74 gy rt |
1 |
2007 |
| Diagnostic Test |
89zr-avelumab pet |
1 |
2018 |
| Drug |
89zr-pembrolizumab |
1 |
2016 |
| Device |
89zr-pembrolizumab pet |
1 |
2016 |
| Drug |
a) standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up |
1 |
2020 |
| Drug |
a) standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up/follow-up for 1 year; |
1 |
2020 |
| Procedure |
a: radiotherapy alone |
1 |
2005 |
| Drug |
ab154 |
1 |
2020 |
| Drug |
abbv-181 |
1 |
2019 |
| Drug |
abbv-184 |
1 |
2020 |
| Drug |
abbv-368 |
1 |
2019 |
| Drug |
abbv-927 |
1 |
2019 |
| Drug |
abexinostat |
1 |
2018 |
| Drug |
abi-007 (abraxane) |
1 |
2006 |
| Drug |
abi-007 (abraxane)/carboplatin |
1 |
2006 |
| Biological |
abi-007/carboplatin/trastuzumab |
1 |
1999 |
| Drug |
abiraterone acetate |
1 |
2016 |
| Drug |
abp 215 |
1 |
2013 |
| Drug |
abraxane |
1 |
2017 |
| Drug |
abraxane (induction) |
1 |
2014 |
| Drug |
abraxane (maintenance) |
1 |
2014 |
| Drug |
abraxane / carboplatin |
1 |
2017 |
| Drug |
abt-869 |
1 |
2008 |
| Drug |
abt-869 .25 mg |
1 |
2007 |
| Drug |
abt-869 .25 mg/kg |
1 |
2007 |
| Drug |
abt-869 0.10 mg |
1 |
2007 |
| Drug |
abt-869 0.10 mg/kg |
1 |
2007 |
| Drug |
abx |
1 |
2013 |
| Drug |
abx/with cisplatin |
1 |
2013 |
| Drug |
ac |
1 |
2017 |
| Drug |
acalabrutinib |
1 |
2015 |
| Radiation |
accelerated conformational radiotherapy |
1 |
2001 |
| Radiation |
accelerated fraction |
1 |
2014 |
| Drug |
acetaminophen |
1 |
2019 |
| Drug |
acridine carboxamide |
1 |
1999 |
| Diagnostic Test |
act-hla |
1 |
2017 |
| Drug |
active comparator (erlotinib) |
1 |
2011 |
| Drug |
acy-241 |
1 |
2015 |
| Drug |
acyclovir |
1 |
2013 |
| Genetic |
ad-ccl21-dc .05 x 07 |
1 |
2018 |
| Genetic |
ad-ccl21-dc 1 x 07 |
1 |
2018 |
| Genetic |
ad-ccl21-dc 3 x 07 |
1 |
2018 |
| Genetic |
ad-ccl21-dc exd |
1 |
2018 |
| Biological |
ad-magea3 |
1 |
2016 |
| Biological |
ad100-gp96ig-hla a1 |
1 |
2007 |
| Other |
adaptated physical activity |
1 |
2019 |
| Drug |
adjuvant bevacizumab |
1 |
2005 |
| Drug |
adjuvant chemotherapy (taxol |
1 |
2009 |
| Drug |
adjuvant chemotherapy (taxol/carboplatin) |
1 |
2009 |
| Drug |
adxs-503 |
1 |
2019 |
| Drug |
afatinib - 1a |
1 |
2013 |
| Drug |
afatinib - 1b |
1 |
2013 |
| Biological |
aflibercept |
1 |
2008 |
| Drug |
aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrapâ®) |
1 |
2007 |
| Drug |
ag-013736 |
1 |
2008 |
| Drug |
ag-013736 (axitinib) |
1 |
2008 |
| Radiation |
aggressive thoracic radiotherapy |
1 |
2018 |
| Drug |
akt inhibitor mk2206 |
1 |
2011 |
| Drug |
albumin-bound paclitaxel |
1 |
2007 |
| Drug |
albumin-bound paclitaxel, carboplatin, toripalimab |
1 |
2020 |
| Drug |
albumin paclitaxel |
1 |
2010 |
| Drug |
albumin paclitaxel/carboplatin |
1 |
2010 |
| Drug |
alclometasone cream |
1 |
2011 |
| Drug |
alectnib |
1 |
2018 |
| Drug |
alflutinib mesylate (ast2818) 80mg |
1 |
2018 |
| Drug |
alflutinib mesylate (ast2818) 80mg//40 mg/ placebo |
1 |
2018 |
| Drug |
alimta injectable product |
1 |
2019 |
| Drug |
alimta/taxotere |
1 |
2007 |
| Drug |
alimtaâ® |
1 |
2006 |
| Device |
alk qpcr assay |
1 |
2013 |
| Drug |
alkotinib |
1 |
2018 |
| Biological |
allogeneic tumour lysate (melcancervac) |
1 |
2007 |
| Drug |
alt-803 / atezolizumab |
1 |
2017 |
| Drug |
alt-803 / avelumab |
1 |
2017 |
| Drug |
alt-803 / nivolumab |
1 |
2017 |
| Drug |
alt-803 / pembrolizumab |
1 |
2017 |
| Drug |
amg 102 |
1 |
2010 |
| Drug |
amg 102/erlotinib |
1 |
2010 |
| Drug |
amg 386 |
1 |
2012 |
| placebo |
amg 386 placebo |
1 |
2012 |
| Drug |
amg 479, everolimus, panitumumab |
1 |
2010 |
| Drug |
amg 510 |
1 |
2020 |
| Drug |
amg 655 |
1 |
2007 |
| placebo |
amg 655 placebo |
1 |
2007 |
| Drug |
amg 951 (rhapo2l |
1 |
2007 |
| Drug |
amg 951 (rhapo2l/trail) |
1 |
2007 |
| Biological |
amg820 |
1 |
2016 |
| Biological |
amg820/pembrolizumab |
1 |
2016 |
| Drug |
amifostine |
1 |
2004 |
| Drug |
aminocamptothecin colloidal dispersion |
1 |
1999 |
| Drug |
anastrozole |
1 |
2016 |
| Procedure |
anatomical segmentectomy, lobectomy |
1 |
2018 |
| Procedure |
anatomical segmentectomy, lobectomy/bilobectomy |
1 |
2018 |
| Drug |
anlotinib hydrochloride capsule |
1 |
2020 |
| Drug |
anlotinib, oral capsule |
1 |
2019 |
| Drug |
anlotinib/icotinib |
1 |
2018 |
| Drug |
anlotinib/with osimertinib |
1 |
2019 |
| Drug |
anlotinib/with pemetrexed/carboplatin |
1 |
2018 |
| Biological |
anti-ny-eso-1 tcr transduced t cells |
1 |
2017 |
| Drug |
anti-pd-l1 monoclonal antibody mpdl3280a |
1 |
2015 |
| Biological |
anti-pd1 |
1 |
2019 |
| Biological |
anti-pd1 antibody-activated tils |
1 |
2019 |
| Drug |
antibody tf2 |
1 |
2010 |
| Other |
antitumor drug screening assay |
1 |
2006 |
| Drug |
ap |
1 |
2017 |
| Drug |
ap/ac |
1 |
2017 |
| Drug |
apatinib 250mg |
1 |
2017 |
| Drug |
apatinib 500mg |
1 |
2017 |
| Drug |
apatinib 750mg |
1 |
2017 |
| Drug |
apatinib mesylate tablet |
1 |
2017 |
| Drug |
apatinib mesylate tablet/with s-1 capsules |
1 |
2017 |
| Drug |
apatinib/with vinorelbine |
1 |
2018 |
| Drug |
apatinib(250mg |
1 |
2019 |
| Drug |
apatinib(250mg/d)/with egfr-tki |
1 |
2019 |
| Drug |
apg-1252 |
1 |
2019 |
| Procedure |
apheresis |
1 |
2009 |
| Drug |
approved anti-pd-1 inhibitor |
1 |
2017 |
| Drug |
apricoxib/erlotinib |
1 |
2008 |
| Drug |
arm a |
1 |
2018 |
| Drug |
arm b |
1 |
2018 |
| Radiation |
arm1 (hypofractionated radiotherapy) |
1 |
2017 |
| Drug |
armodafinil |
1 |
2011 |
| Drug |
asa404 |
1 |
2008 |
| Drug |
ask120067 |
1 |
2018 |
| Drug |
asn007 rd |
1 |
2018 |
| Drug |
asn007: ascending doses |
1 |
2018 |
| Biological |
ast-vac2 |
1 |
2017 |
| Drug |
at-101 |
1 |
2007 |
| Drug |
at-101/docetaxel |
1 |
2007 |
| Drug |
at13387 |
1 |
2012 |
| Drug |
atezolizumab-bevacizumab |
1 |
2019 |
| Drug |
atezolizumab (mpdl3280a), an engineered anti-programmed death-ligand 1 (anti-pd-l1) antibody |
1 |
2015 |
| Drug |
atezolizumab 1200 mg in 20 ml injection |
1 |
2019 |
| Biological |
atl001 |
1 |
2019 |
| Drug |
atovaquone |
1 |
2015 |
| Drug |
atra |
1 |
2009 |
| Drug |
auranofin |
1 |
2012 |
| Biological |
autologous dendritic cell-adenovirus ccl21 vaccine |
1 |
2008 |
| Biological |
autologous dendritic cell cancer vaccine |
1 |
2005 |
| Drug |
autologous dendritic cells pulsed with antigen |
1 |
2019 |
| Genetic |
autologous genetically modified adp-a2m4cd8 cells |
1 |
2019 |
| Biological |
autologous genetically modified t cells, magea10á¶œâ·â¹â¶t |
1 |
2015 |
| Biological |
autologous tcm cells immunotherapy |
1 |
2018 |
| Biological |
autologous wt1-tcrc4 gene-transduced cd8-positive tcm |
1 |
2015 |
| Biological |
autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes |
1 |
2015 |
| Biological |
av-299 |
1 |
2009 |
| Biological |
av-299 / gefitinib |
1 |
2009 |
| Drug |
avastin in combination with paclitaxel |
1 |
2016 |
| Drug |
avastin in combination with paclitaxel/carboplatin |
1 |
2016 |
| Drug |
avastinâ® |
1 |
2017 |
| Drug |
avelumab (msb0010718c) |
1 |
2018 |
| Drug |
avelumab 1200 mg in combination with gemcitabine |
1 |
2017 |
| Drug |
avelumab 1200 mg in combination with gemcitabine/cisplatin |
1 |
2017 |
| Drug |
avelumab 1200 mg in combination with pemetrexed |
1 |
2017 |
| Drug |
avelumab 1200 mg in combination with pemetrexed/carboplatin |
1 |
2017 |
| Drug |
avelumab 800 mg in combination with gemcitabine |
1 |
2017 |
| Drug |
avelumab 800 mg in combination with gemcitabine / cisplatin. |
1 |
2017 |
| Drug |
avelumab 800 mg in combination with pemetrexed |
1 |
2017 |
| Drug |
avelumab 800 mg in combination with pemetrexed / carboplatin |
1 |
2017 |
| Drug |
avitinib maleate |
1 |
2018 |
| Drug |
axitinib (ag-013736) |
1 |
2018 |
| Drug |
azacitidine 30mg |
1 |
2006 |
| Drug |
azacitidine 30mg/m2 |
1 |
2006 |
| Drug |
azacitidine 40mg |
1 |
2006 |
| Drug |
azacitidine 40mg/m2 |
1 |
2006 |
| Drug |
azd2014 |
1 |
2014 |
| Drug |
azd2171 |
1 |
2005 |
| Drug |
azd4205 |
1 |
2018 |
| Drug |
azd4785 |
1 |
2017 |
| Drug |
azd6244 / erlotinib |
1 |
2010 |
| Drug |
azd8931 |
1 |
2014 |
| Drug |
azd9291 40 mg |
1 |
2015 |
| Drug |
azd9291 80 mg/40 mg |
1 |
2015 |
| Drug |
azd9291 80 mg/40 mg / placebo |
1 |
2014 |
| Drug |
azd9291 tablets |
1 |
2014 |
| Drug |
b) improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up |
1 |
2020 |
| Drug |
b) improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up/1 year follow-up; |
1 |
2020 |
| Drug |
b: cbdca |
1 |
2005 |
| Drug |
b: cbdca/radiotherapy |
1 |
2005 |
| Drug |
b12 |
1 |
2008 |
| Drug |
bavituximab/paclitaxel/carboplatin |
1 |
2008 |
| Drug |
bay 43-9006 |
1 |
2007 |
| Drug |
bay 43-9006 (sorafenib) |
1 |
2004 |
| Drug |
bay59-8862 (cytotoxic taxane) |
1 |
2002 |
| Drug |
bcd-100 |
1 |
2017 |
| Drug |
becatecarin |
1 |
2000 |
| Behavioral |
behavioral intervention |
1 |
2018 |
| Drug |
belinostat, carboplatin, paclitaxel |
1 |
2011 |
| Drug |
belloxa |
1 |
2010 |
| Drug |
belotaxel |
1 |
2010 |
| Drug |
belotecan |
1 |
2009 |
| Drug |
berzosertib |
1 |
2015 |
| Other |
best standard of care (bsc) |
1 |
2005 |
| Other |
best support treatment |
1 |
2010 |
| Other |
best supportive care (maintenance) |
1 |
2014 |
| Dietary Supplement |
beta-glucan |
1 |
2008 |
| Drug |
bevacizumab-eu |
1 |
2015 |
| Drug |
bevacizumab-pfizer |
1 |
2015 |
| Drug |
bevacizumab (avastin) |
1 |
2005 |
| Drug |
bevacizumab / pemetrexed |
1 |
2009 |
| Drug |
bevacizumab / pemetrexed / carboplatin |
1 |
2009 |
| Drug |
bevacizumab 15 mg |
1 |
2010 |
| Drug |
bevacizumab 15 mg/kg |
1 |
2010 |
| Drug |
bevacizumab 7.5 mg |
1 |
2010 |
| Drug |
bevacizumab 7.5 mg/kg |
1 |
2010 |
| Drug |
bevacizumab in combination with paclitaxel |
1 |
2016 |
| Drug |
bevacizumab in combination with paclitaxel/carboplatin |
1 |
2016 |
| Drug |
bevacizumab with chemotherapy, pleur-xtm catheter placement |
1 |
2005 |
| Drug |
bevacizumab, oxaliplatin, pemetrexed |
1 |
2005 |
| Drug |
bevacizumab,erlotinib |
1 |
2008 |
| Drug |
bevacizumab/erlotinib |
1 |
2015 |
| Drug |
bevacizumab/pemetrexed/cisplatin |
1 |
2013 |
| Drug |
bexarotene (targretin) |
1 |
2005 |
| Drug |
bexarotene with carboplatin |
1 |
2002 |
| Drug |
bexarotene with carboplatin/paclitaxel |
1 |
2002 |
| Drug |
bgb324 |
1 |
2016 |
| Biological |
bi 1361849 |
1 |
2017 |
| Drug |
bi 6727 |
1 |
2009 |
| Drug |
bi 695502 |
1 |
2014 |
| Drug |
bi 836845 |
1 |
2014 |
| Drug |
bi 836880 |
1 |
2018 |
| Drug |
bi 891065 |
1 |
2017 |
| Drug |
bibf 1120 es high dose |
1 |
2014 |
| Drug |
bibf 1120 es low dose |
1 |
2014 |
| Drug |
bibf 1120 h |
1 |
2009 |
| Drug |
bibf 1120 h / docetaxel h |
1 |
2009 |
| Drug |
bibf 1120 h / docetaxel m |
1 |
2009 |
| Drug |
bibf 1120 l |
1 |
2009 |
| Drug |
bibf 1120 l / docetaxel m |
1 |
2009 |
| Drug |
bibf 1120 m |
1 |
2009 |
| Drug |
bibf 1120 m / docetaxel h |
1 |
2009 |
| Drug |
bibf 1120 m / docetaxel m |
1 |
2009 |
| Drug |
bibf 1120/docetaxel |
1 |
2008 |
| Drug |
bibw 2992 ma2 20mg |
1 |
2008 |
| Drug |
bibw 2992 ma2 20mg/day |
1 |
2008 |
| Drug |
bibw 2992 ma2 40mg |
1 |
2008 |
| Drug |
bibw 2992 ma2 40mg/day |
1 |
2008 |
| Drug |
bibw 2992 ma2 50mg |
1 |
2008 |
| Drug |
bibw 2992 ma2 50mg/day |
1 |
2008 |
| Drug |
bibw 2992 qd |
1 |
2008 |
| Drug |
bibw2992 |
1 |
2008 |
| Drug |
bibw2992 / paclitaxel |
1 |
2008 |
| Drug |
biib022 with paclitaxel |
1 |
2009 |
| Drug |
biib022 with paclitaxel/carboplatin |
1 |
2009 |
| Procedure |
bilobectomy |
1 |
2018 |
| Drug |
bind-014 |
1 |
2013 |
| Drug |
bind-014 (docetaxel nanoparticles for injectable suspension) |
1 |
2014 |
| Drug |
bio-11006 |
1 |
2018 |
| Drug |
bio-11006/standard of care |
1 |
2018 |
| Drug |
bio 300 oral suspension |
1 |
2015 |
| Procedure |
biopsy of a metastatic lesion. |
1 |
2013 |
| Procedure |
biopsy samples |
1 |
2005 |
| Procedure |
biospecimen collection |
1 |
2017 |
| Drug |
bisphosphates |
1 |
2008 |
| Drug |
bkm120/erlotinib |
1 |
2011 |
| Other |
blood |
1 |
2012 |
| Diagnostic Test |
blood-sampled |
1 |
2018 |
| Biological |
blood-stage infection of p. vivax |
1 |
2016 |
| Other |
blood collection |
1 |
2019 |
| Procedure |
blood draw |
1 |
2018 |
| Procedure |
blood oxygen level dependent imaging |
1 |
2019 |
| Procedure |
blood sample for methylation analysis |
1 |
2010 |
| Other |
blood withdrawal |
1 |
2016 |
| Drug |
bms-813160 |
1 |
2019 |
| Drug |
bms-986253 |
1 |
2019 |
| Drug |
bnp7787 |
1 |
2004 |
| Procedure |
bone marrow aspiration from the iliac crest |
1 |
2015 |
| Drug |
bosutinib |
1 |
2017 |
| Drug |
bpi-15086 |
1 |
2016 |
| Drug |
bpi-7711 capsule |
1 |
2017 |
| Drug |
bpi-9016m |
1 |
2016 |
| Radiation |
brachytherapy |
1 |
2005 |
| Device |
breath actuated nebulizer |
1 |
2017 |
| Other |
breath collection |
1 |
2019 |
| Radiation |
breath holding |
1 |
2006 |
| Procedure |
breath test |
1 |
2013 |
| Device |
bronchoscopic thermal vapor ablation |
1 |
2017 |
| Drug |
bryostatin 1 |
1 |
2000 |
| Drug |
bsc |
1 |
2012 |
| Drug |
ca |
1 |
2018 |
| Drug |
ca/nivolumab |
1 |
2018 |
| Drug |
cabazitaxel |
1 |
2013 |
| Drug |
cabazitaxel-xrp6258 (3-week cycle) |
1 |
2011 |
| Drug |
cabazitaxel-xrp6258 (5-week cycle) |
1 |
2011 |
| Drug |
cabiralizumab |
1 |
2018 |
| Drug |
cabozantinib 20 mg |
1 |
2019 |
| Drug |
cabozantinib 40 mg |
1 |
2019 |
| Drug |
cabozantinib 60 mg |
1 |
2019 |
| Drug |
calcitriol |
1 |
2003 |
| Drug |
calcitriol / docetaxel |
1 |
2003 |
| Drug |
camrelizumab/with albumin-bound paclitaxel/cisplatin |
1 |
2020 |
| placebo |
canakinumab matching placebo |
1 |
2018 |
| Drug |
canfosfamide hydrochloride |
1 |
2002 |
| Device |
capp-seq |
1 |
2016 |
| Biological |
car-t cells |
1 |
2018 |
| Combination Product |
car-t combining pd-1 knockout |
1 |
2018 |
| Drug |
carboplatin-based |
1 |
2013 |
| Drug |
carboplatin-based chemotherapy |
1 |
2008 |
| Drug |
carboplatin-nab-paclitaxel |
1 |
2017 |
| Drug |
carboplatin-paclitaxel |
1 |
2017 |
| Drug |
carboplatin-taxol-radiotherapy |
1 |
2005 |
| Drug |
carboplatin (area under the concentration curve [auc] 6) |
1 |
2008 |
| Drug |
carboplatin (auc 5) |
1 |
2010 |
| Drug |
carboplatin (auc 6) |
1 |
2010 |
| Drug |
carboplatin (dose level 1) |
1 |
2018 |
| Drug |
carboplatin (dose level 2) |
1 |
2018 |
| Drug |
carboplatin (induction) |
1 |
2014 |
| Drug |
carboplatin (palaplatin) |
1 |
2008 |
| Drug |
carboplatin ,pemetrexed |
1 |
2018 |
| Drug |
carboplatin / pemetrexed / atezolizumab |
1 |
2019 |
| Drug |
carboplatin / pemetrexed / atezolizumab / bevacizumab |
1 |
2019 |
| Drug |
carboplatin // gemcitabine // docetaxel //cisplatin |
1 |
2007 |
| Drug |
carboplatin area under the curve (auc)5 |
1 |
2016 |
| Drug |
carboplatin auc |
1 |
2019 |
| Drug |
carboplatin auc 2 |
1 |
2012 |
| Drug |
carboplatin auc 5 mg |
1 |
2013 |
| Drug |
carboplatin auc 5 mg/ml/min |
1 |
2013 |
| Drug |
carboplatin auc 6 |
1 |
2017 |
| Drug |
carboplatin auc 6 mg |
1 |
2013 |
| Drug |
carboplatin auc 6 mg/ml/min |
1 |
2013 |
| Drug |
carboplatin auc2 |
1 |
2018 |
| Drug |
carboplatin injection |
1 |
2020 |
| Drug |
carboplatin paclitaxel |
1 |
2018 |
| Drug |
carboplatin pemetrexed |
1 |
2017 |
| Drug |
carboplatin therapy |
1 |
2008 |
| Drug |
carboplatin, 5 mg |
1 |
2008 |
| Drug |
carboplatin, 6 mg |
1 |
2008 |
| Drug |
carboplatin, pemetrexed |
1 |
2008 |
| Drug |
carboplatin, pemetrexed/bevacizumab |
1 |
2008 |
| Drug |
carboplatin,pemetrexed |
1 |
2018 |
| Drug |
carboplatin/ paclitaxel |
1 |
2018 |
| Drug |
carboplatin/gemcitabine, carboplatin/taxol |
1 |
2005 |
| Drug |
carboplatin/nab paclitaxel |
1 |
2019 |
| Drug |
carboplatin/paclitaxel (cp) |
1 |
2004 |
| Drug |
carboplatin/paclitaxel/medi-575 |
1 |
2010 |
| Drug |
carboplatine |
1 |
2005 |
| Drug |
carboxyamidotriazole |
1 |
1999 |
| Behavioral |
carevive cps |
1 |
2017 |
| Drug |
carotuximab (trc105) |
1 |
2017 |
| Drug |
cb-839 |
1 |
2016 |
| Drug |
cbp501 |
1 |
2009 |
| Drug |
cbp501 / cisplatin / pemetrexed |
1 |
2009 |
| Drug |
cc-223, erlotinib |
1 |
2012 |
| Drug |
cc-223, oral azacitidine |
1 |
2012 |
| Drug |
cc-5013 |
1 |
2005 |
| Biological |
cccr-nk92 cells |
1 |
2018 |
| Drug |
ccrt arm without consolidation chemotherapy |
1 |
2006 |
| Drug |
cddp |
1 |
2005 |
| Drug |
cdp791 10mg |
1 |
2005 |
| Drug |
cdp791 10mg/kg |
1 |
2005 |
| Drug |
cdp791 20mg |
1 |
2005 |
| Drug |
cdp791 20mg/kg |
1 |
2005 |
| Drug |
cdx-1127 |
1 |
2011 |
| Drug |
cediranib |
1 |
2017 |
| Drug |
cemiplimab regn2810 |
1 |
2017 |
| Behavioral |
center for epidemiological studies depression scale |
1 |
2015 |
| Radiation |
centrally located lung tumor |
1 |
2009 |
| Drug |
centrum |
1 |
2012 |
| Drug |
ceritinib (ldk378) |
1 |
2015 |
| Drug |
cetuximab / cisplatin / vinorelbine |
1 |
2005 |
| Drug |
cetuximab / gefitinib |
1 |
2005 |
| Drug |
cetuximab / platinum / gemcitabine |
1 |
2005 |
| Drug |
cetuximab 250 mg |
1 |
2009 |
| Drug |
cetuximab 250 mg/m^2 |
1 |
2009 |
| Drug |
cetuximab 500 mg |
1 |
2009 |
| Drug |
cetuximab 500 mg/m^2 |
1 |
2009 |
| Drug |
cetuximab in combination with carboplatin |
1 |
2009 |
| Drug |
cetuximab in combination with carboplatin/gemcitabine |
1 |
2009 |
| Drug |
cetuximab/platinum-based doublet chemotherapy |
1 |
2009 |
| Biological |
cg8123 |
1 |
2004 |
| Other |
chemo-irradiation |
1 |
2004 |
| Radiation |
chemoradiotherapy |
1 |
2016 |
| Other |
chemoradiotherapy regimen between pc |
1 |
2011 |
| Other |
chemoradiotherapy regimen between pc/pe |
1 |
2011 |
| Radiation |
chemoradiotherapy with integrated boost dose |
1 |
2016 |
| Drug |
chemort |
1 |
2018 |
| Other |
chemotherapy (arm a only) |
1 |
2019 |
| Other |
chemotherapy concurrent with radiotherapy |
1 |
2019 |
| Other |
chemotherapy/radiotherapy |
1 |
2009 |
| Procedure |
chemotherapy/surgery |
1 |
2006 |
| Procedure |
chest radiotherapy |
1 |
1999 |
| Diagnostic Test |
chest xray |
1 |
2018 |
| Drug |
chinese traditional medicine xh1 |
1 |
2018 |
| Drug |
ci-1040 |
1 |
2002 |
| Drug |
ci 1033 |
1 |
2005 |
| Drug |
cilengitide |
1 |
2009 |
| Drug |
cilengitide, radiochemotherapy |
1 |
2010 |
| Drug |
cisplatin-gemzar |
1 |
2005 |
| Drug |
cisplatin-navelbine-radiotherapy |
1 |
2005 |
| Drug |
cisplatin (dose level 1) |
1 |
2018 |
| Drug |
cisplatin (dose level 2) |
1 |
2018 |
| Drug |
cisplatin (dose level 3) |
1 |
2018 |
| Drug |
cisplatin (dose level 4) |
1 |
2018 |
| Drug |
cisplatin / docetaxel |
1 |
2008 |
| Drug |
cisplatin / docetaxel / enoxaparin |
1 |
2008 |
| Drug |
cisplatin / pemetrexed |
1 |
2009 |
| Drug |
cisplatin / vinorelbine |
1 |
2005 |
| Drug |
cisplatin followed by gemcitabine |
1 |
2007 |
| Drug |
cisplatin intercalating gefitinib |
1 |
2017 |
| Drug |
cisplatin iv |
1 |
2009 |
| Drug |
cisplatin phase 1 |
1 |
2007 |
| Drug |
cisplatin phase 2 |
1 |
2007 |
| Drug |
cisplatin with concomitant radiotherapy 66 gy (total dose) |
1 |
2008 |
| Drug |
cisplatin) |
1 |
2007 |
| Drug |
cisplatin, dexamethasone,vitamin b12, folic acid |
1 |
2010 |
| Drug |
cisplatin, docetaxel |
1 |
2008 |
| Drug |
cisplatin, gemcitabine |
1 |
2010 |
| Drug |
cisplatin, ifosfamide, gemcitabine |
1 |
2008 |
| Drug |
cisplatin, vinorlebine, cetuximab |
1 |
2009 |
| Drug |
cisplatin. |
1 |
2017 |
| Drug |
cisplatin/ etoposide |
1 |
2018 |
| Drug |
cisplatin/carboplatin-based |
1 |
2013 |
| Drug |
cisplatin/carboplatin,pemetrexed |
1 |
2018 |
| Drug |
cisplatin/docetaxel |
1 |
2007 |
| Drug |
cisplatin/gemcitabine |
1 |
2018 |
| Drug |
cisplatin/pemetrexed |
1 |
2015 |
| Procedure |
cisplatin/radiation therapy |
1 |
2007 |
| Drug |
cisplatin/vinorelbine |
1 |
2007 |
| Drug |
cisplatin; etoposide; radiation therapy; docetaxel; neulasta |
1 |
2008 |
| Drug |
cisplatine |
1 |
2005 |
| Drug |
cisplatine, etoposide, cetuximab |
1 |
2009 |
| Drug |
cisplatinum (50mg |
1 |
2012 |
| Drug |
cisplatinum (50mg/m2) iv (in the vein) on day 1/day 8 of a 28-day cycle for 2 cycles |
1 |
2012 |
| Device |
ck |
1 |
2009 |
| Drug |
ck-101 |
1 |
2016 |
| Drug |
ck-301 (cosibelimab) |
1 |
2017 |
| Drug |
cln-081 |
1 |
2019 |
| Drug |
cmp-001 |
1 |
2018 |
| Drug |
cofetuzumab pelidotin |
1 |
2019 |
| Procedure |
cognitive assessment |
1 |
2016 |
| Drug |
combination carboplatin |
1 |
2004 |
| Drug |
combination carboplatin/paclitaxel |
1 |
2004 |
| Drug |
combination chemotherapy (pemetrexed |
1 |
2007 |
| Drug |
combination chemotherapy (pemetrexed / cisplatin) |
1 |
2007 |
| Biological |
combination nivolumab |
1 |
2017 |
| Biological |
combination nivolumab/ipilimumab |
1 |
2017 |
| Drug |
combination of arixtra with chemotherapy |
1 |
2007 |
| Drug |
combination of nktr-214 |
1 |
2016 |
| Drug |
combination of nktr-214 / nivolumab |
1 |
2016 |
| Drug |
combination of nktr-214 / nivolumab / ipilimumab |
1 |
2016 |
| Drug |
combination of sorafenib |
1 |
2009 |
| Drug |
combination of sorafenib/everolimus |
1 |
2009 |
| Drug |
combo pbf-509 (160 mg) |
1 |
2015 |
| Drug |
combo pbf-509 (160 mg) / pdr001 |
1 |
2015 |
| Drug |
combo pbf-509 (320 mg) |
1 |
2015 |
| Drug |
combo pbf-509 (320 mg) / pdr001 |
1 |
2015 |
| Drug |
combo pbf-509 (640 mg) |
1 |
2015 |
| Drug |
combo pbf-509 (640 mg) / pdr001 |
1 |
2015 |
| Other |
communication intervention |
1 |
2012 |
| Radiation |
comparator: ct |
1 |
2008 |
| Radiation |
comparator: ct/mri/fdg-pet |
1 |
2008 |
| Drug |
comparator: erlotinib |
1 |
2008 |
| Drug |
comparator: erlotinib / dalotuzumab |
1 |
2008 |
| Drug |
comparator: erlotinib monotherapy |
1 |
2008 |
| Behavioral |
comparison group) |
1 |
2013 |
| Drug |
compound 121564 |
1 |
2018 |
| Procedure |
computed tomography-guided optical sensor-guided radiofrequency ablation |
1 |
2005 |
| Drug |
concomitant docetaxel 20mg |
1 |
2012 |
| Radiation |
concomitant radiotherapy |
1 |
2017 |
| Drug |
concomitant rdt 2gy |
1 |
2012 |
| Other |
concurrent chemo-therapy |
1 |
2010 |
| Radiation |
concurrent chemoradiotherapy |
1 |
2014 |
| Drug |
concurrent chemoradiotherapy (paclitaxel |
1 |
2008 |
| Drug |
concurrent chemoradiotherapy (paclitaxel/cisplatin/radiotherapy) |
1 |
2008 |
| Radiation |
concurrent thoracic radiation therapy |
1 |
2006 |
| Procedure |
cone-beam computed tomography |
1 |
2018 |
| Radiation |
conformal radiotherapy |
1 |
2006 |
| Radiation |
conformal thoracic radiotherapy (ctrt) |
1 |
2008 |
| Drug |
consolidation chemotherapy with docetaxel |
1 |
2006 |
| Drug |
consolidation chemotherapy with docetaxel/cisplatin |
1 |
2006 |
| Drug |
consolidation sintilimab |
1 |
2019 |
| Drug |
consolidative durvalumab |
1 |
2019 |
| Radiation |
contralateral esophageal sparing technique (cest) |
1 |
2015 |
| Other |
control |
1 |
2017 |
| Other |
control / |
1 |
2017 |
| Drug |
control arm (seq): |
1 |
2006 |
| Radiation |
conventional fractionation |
1 |
2014 |
| Radiation |
conventional radiation |
1 |
2011 |
| Radiation |
conventional radiotherapy |
1 |
2016 |
| Radiation |
conventional radiotherapy (crt) |
1 |
2013 |
| Radiation |
conventionally fractionated radiotherapy (conrt) |
1 |
2009 |
| Other |
copd assessment test |
1 |
2020 |
| Other |
copd assessment test/modified medical research council dyspnea patient reported outcomes |
1 |
2020 |
| Device |
coredx pulmonary mini-forceps |
1 |
2019 |
| Other |
counseling |
1 |
2019 |
| Drug |
cp-675,206 |
1 |
2006 |
| Drug |
cp-751,871 / carboplatin / paclitaxel |
1 |
2008 |
| Drug |
cpg 7909 |
1 |
2003 |
| Drug |
cpi-444 |
1 |
2017 |
| Drug |
cpl304110 |
1 |
2019 |
| Drug |
crlx101 |
1 |
2011 |
| Drug |
cross-over to osimertinib |
1 |
2014 |
| Procedure |
cryobiopsy |
1 |
2019 |
| Device |
cryosurgery |
1 |
2016 |
| Drug |
cs-1008 |
1 |
2009 |
| Drug |
cs7017 tablets |
1 |
2008 |
| Device |
ct-simulation |
1 |
2011 |
| Device |
ct-simulation/4d pet-ct |
1 |
2011 |
| Other |
ct for the diagnosis |
1 |
2016 |
| Other |
ct perfusion imaging |
1 |
2012 |
| Diagnostic Test |
ct scans |
1 |
2018 |
| Drug |
ct053ptsa |
1 |
2018 |
| Other |
ctdna analysis |
1 |
2019 |
| Diagnostic Test |
ctdna blood sample |
1 |
2019 |
| Biological |
ctl |
1 |
2019 |
| Drug |
cudc-101 |
1 |
2010 |
| Drug |
custirsen sodium |
1 |
2005 |
| Drug |
customized treatment |
1 |
2008 |
| Biological |
cv301 |
1 |
2016 |
| Biological |
cv9201 |
1 |
2009 |
| Biological |
cva21 |
1 |
2016 |
| Biological |
cxcr5 modified egfr chimeric antigen receptor autologous t cells |
1 |
2019 |
| Radiation |
cyberknife stereotactic radiosurgery |
1 |
2008 |
| Radiation |
cyclical hypofractionated palliative radiation (quad shot) |
1 |
2020 |
| Drug |
cyclophosphamide/fludarabine |
1 |
2017 |
| Genetic |
cytogenetic analysis |
1 |
2003 |
| Drug |
d |
1 |
2012 |
| Drug |
d-0316 capsule |
1 |
2019 |
| Radiation |
daily hyperfractionated radiation therapy |
1 |
2017 |
| Radiation |
daily stereotactic body radiotherapy |
1 |
2018 |
| Drug |
daratumumab |
1 |
2016 |
| Drug |
dasatinib - 1a |
1 |
2013 |
| Drug |
dasatinib - 1b |
1 |
2013 |
| Other |
data feedback only |
1 |
2012 |
| Drug |
day 8 of a 28-day cycle for 2 cycles |
1 |
2012 |
| Biological |
dc vaccine |
1 |
2016 |
| Other |
dce-mri scan |
1 |
2012 |
| Drug |
debio 1143 |
1 |
2017 |
| Behavioral |
decision support tool |
1 |
2019 |
| Drug |
decitabine (dac) |
1 |
2017 |
| Drug |
decitabine in combination with genistein |
1 |
2012 |
| Drug |
defactinib |
1 |
2016 |
| Drug |
defactinib (vs-6063) |
1 |
2013 |
| Drug |
demcizumab |
1 |
2010 |
| Biological |
denileukin diftitox |
1 |
2005 |
| Drug |
denosumab-nivolumab combination |
1 |
2018 |
| Biological |
depsipeptide |
1 |
2002 |
| Drug |
desloratadine |
1 |
2015 |
| Drug |
detox-b adjuvant |
1 |
2007 |
| Device |
device for pet |
1 |
2016 |
| Biological |
dex2 |
1 |
2010 |
| Drug |
dexamethasone (or corticosteroid equivalent) |
1 |
2008 |
| Drug |
dexamethasone (pre- |
1 |
2007 |
| Drug |
dexamethasone (pre-/post-medication for docetaxel) |
1 |
2007 |
| Drug |
d) |
1 |
2019 |
| Procedure |
diagnostic thoracoscopy |
1 |
1999 |
| Other |
dietary fasted |
1 |
2014 |
| Other |
dietary high fat |
1 |
2014 |
| Behavioral |
dignity therapy |
1 |
2014 |
| Drug |
diphenhydramine |
1 |
2019 |
| Drug |
diprosone |
1 |
2009 |
| Procedure |
dissection of the inferior pulmonary ligament |
1 |
2019 |
| Drug |
dkn-01 |
1 |
2011 |
| Drug |
dky709 |
1 |
2019 |
| Drug |
dmxaa in combination with carboplatin |
1 |
2009 |
| Drug |
dmxaa in combination with carboplatin/paclitaxel |
1 |
2009 |
| Drug |
docetaxel-carboplatin |
1 |
2009 |
| Drug |
docetaxel (d) |
1 |
2015 |
| Drug |
docetaxel (taxane) |
1 |
2005 |
| Drug |
docetaxel / plinabulin (dp) |
1 |
2015 |
| Drug |
docetaxel 20mg |
1 |
2012 |
| Drug |
docetaxel 20mg/m2/week / carboplatin auc 2/weekly - concomitant chemoradiation 2gy/day |
1 |
2012 |
| Drug |
docetaxel 40mg<7m2 d1,8, 21, 28 |
1 |
2012 |
| Drug |
docetaxel 40mg<7m2 d1,8, 21, 28/ gemcitabine 1200mg/m2 d1,8, 21, 28 / concomitant docetaxel 20mg/m2/w/carboplatin auc 2/w/ concomitant rdt 2gy/d |
1 |
2012 |
| Drug |
docetaxel 60 mg |
1 |
2012 |
| Drug |
docetaxel 60 mg/m2 |
1 |
2012 |
| Drug |
docetaxel 75 mg/m^2 |
1 |
2016 |
| Drug |
docetaxel 75 mg/m2 |
1 |
2012 |
| Procedure |
docetaxel alone |
1 |
2010 |
| Drug |
docetaxel combination |
1 |
2003 |
| Drug |
docetaxel h |
1 |
2009 |
| Drug |
docetaxel m |
1 |
2009 |
| Drug |
docetaxel, bevacizumab |
1 |
2016 |
| Drug |
docetaxel, cisplatin |
1 |
2005 |
| Drug |
docetaxel/bavituximab/placebo |
1 |
2010 |
| Drug |
docetaxel/carboplatin/bevacizumab/erlotinib |
1 |
2007 |
| Drug |
docetaxel/cddp |
1 |
2005 |
| Drug |
docetaxel/cisplatin followed by gemcitabine |
1 |
2007 |
| Drug |
docetaxel/gemcitabine |
1 |
2007 |
| Drug |
docetaxel/oxaliplatin |
1 |
2016 |
| Drug |
docetaxel/reolysin |
1 |
2012 |
| Drug |
docetaxelâ® |
1 |
2016 |
| Drug |
donafenib tablets |
1 |
2019 |
| Biological |
donor-derived nk cell infusion |
1 |
2017 |
| Procedure |
dose escalation (radiotherapy treatment schedule) |
1 |
2005 |
| Drug |
dose escalation followed by treatment with mtd |
1 |
2012 |
| Biological |
dostarlimab |
1 |
2017 |
| Genetic |
dotap:chol-fus1 |
1 |
2003 |
| Drug |
dovitinib |
1 |
2012 |
| Drug |
doxil |
1 |
2015 |
| Drug |
doxycline |
1 |
2007 |
| Drug |
doxycycline |
1 |
2011 |
| Biological |
drug: hyperacute lung cancer cell vaccine |
1 |
2003 |
| Drug |
ds-1062a |
1 |
2018 |
| Procedure |
dual-agent therapy |
1 |
2010 |
| Procedure |
dual-agent therapy/docetaxel alone/best supportive care |
1 |
2010 |
| Drug |
duravalumab |
1 |
2014 |
| Drug |
durvalumab (medi 4736) |
1 |
2017 |
| Combination Product |
durvalumab / danvatirsen |
1 |
2018 |
| Biological |
durvalumab /tremelimumab |
1 |
2015 |
| Other |
durvalumab/sbrt |
1 |
2016 |
| Drug |
dv281 |
1 |
2017 |
| Drug |
dv281 (rp2d) |
1 |
2017 |
| Procedure |
dynamic contrast-enhanced magnetic resonance imaging |
1 |
2008 |
| Drug |
dzd9008 |
1 |
2019 |
| Drug |
e7080 |
1 |
2009 |
| Drug |
e7389 21 day cycle |
1 |
2005 |
| Drug |
e7389 28 day cycle |
1 |
2005 |
| Dietary Supplement |
eaa |
1 |
2010 |
| Dietary Supplement |
eaa/leu vs total aa |
1 |
2010 |
| Procedure |
ebus-tbna, eus-na |
1 |
2017 |
| Drug |
ec145 |
1 |
2012 |
| Drug |
ec145 / docetaxel |
1 |
2012 |
| Drug |
ec1456 |
1 |
2013 |
| Drug |
ec1456/ec20 |
1 |
2013 |
| Drug |
efaproxiral |
1 |
2000 |
| Drug |
eftilagimod alpha |
1 |
2018 |
| Biological |
egf-pti |
1 |
2018 |
| Drug |
egfr-tk inhibitor |
1 |
2018 |
| Drug |
egfr-tki |
1 |
2015 |
| Genetic |
egfr mutation test |
1 |
2009 |
| Drug |
egfr/egfrviii inhibitor wsd0922-fu |
1 |
2019 |
| Drug |
egfrviii inhibitor wsd0922-fu |
1 |
2019 |
| Drug |
ekb-569 |
1 |
2003 |
| Drug |
eloxatin (gemox) |
1 |
2004 |
| Drug |
emb-01 |
1 |
2018 |
| Drug |
emd 273066 |
1 |
2005 |
| Biological |
emd 521873 |
1 |
2009 |
| Drug |
emibetuzumab |
1 |
2013 |
| Drug |
encorafenib |
1 |
2019 |
| Procedure |
endobronchial ultrasound-guided transbronchial needle aspiration (ebus-tbna) |
1 |
2016 |
| Procedure |
endobronchial ultrasound (ebus) |
1 |
2010 |
| Procedure |
endobronchial ultrasound (ebus) transbronchial needle aspirate (tbna) |
1 |
2017 |
| Procedure |
endobronchial ultrasound guided transthoracic needle biopsy |
1 |
2006 |
| Procedure |
endoscopic ultrasound staging |
1 |
2007 |
| Drug |
endostar -continued pumping into |
1 |
2012 |
| Drug |
endostar -continued pumping into/gp |
1 |
2012 |
| Drug |
endostar -injecting into |
1 |
2012 |
| Drug |
endostar -injecting into /gp |
1 |
2012 |
| Drug |
endostar(recombinant human endostatin injection) |
1 |
2008 |
| Drug |
endostatin |
1 |
2015 |
| Dietary Supplement |
energy goal-based ons |
1 |
2018 |
| Behavioral |
enhanced care (intervention group |
1 |
2013 |
| Behavioral |
enhanced care (intervention group/comparison group) |
1 |
2013 |
| Biological |
enoblituzumab/ipilimumab |
1 |
2015 |
| Drug |
enoxaparin |
1 |
2008 |
| Drug |
ensartinib with fed |
1 |
2018 |
| Drug |
ensartinib with fed/fasting |
1 |
2018 |
| Biological |
enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, endothelial cell progenitor characterization by primary cell cultures |
1 |
2009 |
| Drug |
enzalutamide |
1 |
2016 |
| Drug |
enzastaurin hcl |
1 |
2005 |
| Drug |
enzyme inhibitor therapy |
1 |
2017 |
| Behavioral |
eortc qlq-c30 questionnaire |
1 |
2020 |
| Biological |
ep2101 |
1 |
2003 |
| Drug |
epacadostat 100 mg |
1 |
2016 |
| Drug |
epacadostat 25 mg |
1 |
2016 |
| Drug |
epacadostat 300 mg |
1 |
2016 |
| Drug |
epirubicin |
1 |
2005 |
| Biological |
epoetin alfa |
1 |
2002 |
| Drug |
epothilone |
1 |
2002 |
| Drug |
epothilone d |
1 |
2004 |
| Behavioral |
eq-5d |
1 |
2015 |
| Drug |
erbitux |
1 |
2010 |
| Drug |
erdafitinib |
1 |
2016 |
| Drug |
eribulin |
1 |
2011 |
| Drug |
eribulin in combination |
1 |
2013 |
| Drug |
eribulin mesylate / erlotinib |
1 |
2010 |
| Drug |
erlotinib (tarceva)/bexarotene (targretin) |
1 |
2005 |
| Drug |
erlotinib / docetaxel |
1 |
2011 |
| Drug |
erlotinib / placebo |
1 |
2007 |
| Drug |
erlotinib / sorafenib |
1 |
2007 |
| Drug |
erlotinib 150 |
1 |
2014 |
| Drug |
erlotinib 150/100 mg |
1 |
2014 |
| Drug |
erlotinib in combination with capecitabine |
1 |
2009 |
| Drug |
erlotinib in combination with dasatinib |
1 |
2007 |
| Drug |
erlotinib, bevacizumab |
1 |
2010 |
| Drug |
erlotinib, sunitinib |
1 |
2007 |
| Drug |
erlotinib/bevacizumab |
1 |
2017 |
| Drug |
erlotinib/bexarotene |
1 |
2005 |
| Drug |
erlotinib/placebo |
1 |
2008 |
| Drug |
erythromycin [eritex] |
1 |
2008 |
| Procedure |
escalation of dose (radiotherapy treatment) |
1 |
2005 |
| Radiation |
esophageal-sparing intensity-modulated radiotherapy |
1 |
2016 |
| Radiation |
esophageal sparing imrt |
1 |
2009 |
| Drug |
ethaselen |
1 |
2014 |
| Device |
ethicon powered vascular stapler |
1 |
2016 |
| Drug |
etirinotecan pegol (nktr-102) |
1 |
2013 |
| Drug |
etoposide (50mg |
1 |
2012 |
| Drug |
etoposide (50mg/m2) iv (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles |
1 |
2012 |
| Drug |
etoposide (dose level 1) |
1 |
2018 |
| Drug |
etoposide (dose level 2) |
1 |
2018 |
| Drug |
etoposide 100 mg |
1 |
2013 |
| Drug |
etoposide 100 mg/m^2 |
1 |
2013 |
| Drug |
eu-approved avastinâ® |
1 |
2017 |
| Behavioral |
european organization for research |
1 |
2015 |
| Behavioral |
european organization for research/treatment of cancer quality of life questionnaire c30 |
1 |
2015 |
| Behavioral |
european organization for research/treatment of cancer quality of life questionnaire lc-13 |
1 |
2015 |
| Other |
evaluation of response by recist |
1 |
2017 |
| Other |
evozac calming skin spray |
1 |
2012 |
| Drug |
ex vivo-expanded her2-specific t cells |
1 |
2005 |
| Drug |
exatecan mesylate |
1 |
2000 |
| Device |
exatherm-tbh system |
1 |
2015 |
| Other |
exercise / |
1 |
2017 |
| Behavioral |
exercise intervention |
1 |
2013 |
| Other |
exhaled breath collection |
1 |
2019 |
| Drug |
experimental arm (con): |
1 |
2006 |
| Other |
experimental intervention |
1 |
2016 |
| Drug |
experimental: rp2d (pbf-509 |
1 |
2015 |
| Drug |
experimental: rp2d (pbf-509/pdr001)_immuno treated |
1 |
2015 |
| Radiation |
external beam radiation (dose level 1) |
1 |
2018 |
| Radiation |
external beam radiation (dose level 2) |
1 |
2018 |
| Radiation |
external beam radiation (hyperfractionated) |
1 |
2018 |
| Radiation |
external beam radiation (standard) |
1 |
2018 |
| Drug |
famitinib h |
1 |
2015 |
| Drug |
famitinib h / docetaxel |
1 |
2015 |
| Drug |
famitinib l |
1 |
2015 |
| Drug |
famitinib l / docetaxel |
1 |
2015 |
| Drug |
famitinib m |
1 |
2015 |
| Drug |
famitinib m / docetaxel |
1 |
2015 |
| Drug |
fasting |
1 |
2018 |
| Other |
fasting-mimicking diet |
1 |
2018 |
| Drug |
fate-nk100 |
1 |
2017 |
| Procedure |
fatigue assessment |
1 |
1999 |
| Procedure |
fatigue assessment/management |
1 |
1999 |
| Device |
faza pet scan |
1 |
2015 |
| Drug |
fdg |
1 |
2009 |
| Other |
feces samples |
1 |
2018 |
| Drug |
fexofenadine tablet dosing |
1 |
2016 |
| Device |
fiber optic |
1 |
2016 |
| Biological |
filgrastim |
1 |
1999 |
| Drug |
filgrastim-sd |
1 |
2002 |
| Drug |
filgrastim-sd/01 |
1 |
2002 |
| Drug |
first-line chemotherapy agents |
1 |
2006 |
| Drug |
fisiogel |
1 |
2008 |
| Other |
fitbit |
1 |
2018 |
| Drug |
fkb238 (bevacizumab) |
1 |
2016 |
| Drug |
flt |
1 |
2009 |
| Drug |
flt3 ligand therapy (cdx-301) |
1 |
2016 |
| Genetic |
fluorescence in situ hybridization |
1 |
2007 |
| Drug |
fluorine f 18 ara-g |
1 |
2019 |
| Radiation |
fluorine f 18 ef5 |
1 |
2009 |
| Other |
fluorine f 18 fluorothymidine |
1 |
2007 |
| Drug |
fluoro-d-glucose |
1 |
2010 |
| Drug |
fluoro-l-thymidine |
1 |
2010 |
| Drug |
fluorouracil |
1 |
2006 |
| Drug |
fluoxetine |
1 |
2000 |
| Drug |
folate |
1 |
2005 |
| Drug |
folfox (oxaliplatin |
1 |
2013 |
| Drug |
folfox (oxaliplatin/leucovorin/5-fluorouracil) |
1 |
2013 |
| Drug |
follow-up for 1 year; |
1 |
2020 |
| Procedure |
forceps biopsy |
1 |
2019 |
| Drug |
fosbretabulin |
1 |
2008 |
| Drug |
fostamatinib disodium |
1 |
2009 |
| Procedure |
four dimensional computed tomographic imaging (4dct) |
1 |
2016 |
| Radiation |
fr. x 3 fractions |
1 |
2013 |
| Drug |
fr901228 |
1 |
2007 |
| Radiation |
fraction |
1 |
2018 |
| Radiation |
free breathing |
1 |
2006 |
| Biological |
fresolimumab |
1 |
2015 |
| Combination Product |
fsrt |
1 |
2020 |
| Combination Product |
fsrt/with bevacizumab |
1 |
2020 |
| Drug |
fulvestrant |
1 |
2005 |
| Procedure |
functional imaging of treatment effects |
1 |
2005 |
| Radiation |
functionally adapted, dose escalated vmat radiotherapy |
1 |
2018 |
| Drug |
fusidic acid [verutex] |
1 |
2008 |
| Drug |
g-csf (pegfilgrastim) 3.6 mg |
1 |
2013 |
| Drug |
g1t38 |
1 |
2018 |
| Drug |
gadolinium-dpta |
1 |
2010 |
| Drug |
galunisertib |
1 |
2015 |
| Drug |
gamma-secretase inhibitor ro4929097 |
1 |
2010 |
| Drug |
ganetespib |
1 |
2012 |
| Biological |
gb222 |
1 |
2019 |
| Drug |
gb226 |
1 |
2019 |
| Drug |
gdc-0994 |
1 |
2015 |
| placebo |
gefitinib-matching placebo 250 mg |
1 |
2020 |
| Drug |
gefitinib 250mg |
1 |
2009 |
| Drug |
gefitinib 500mg |
1 |
2009 |
| Drug |
gefitinib 500mg/gefitinib 250mg |
1 |
2009 |
| Drug |
gefitinib retreatment |
1 |
2009 |
| Drug |
gefitinib, pemetrexed,cisplatin |
1 |
2017 |
| Drug |
gefitinib/bkm120 |
1 |
2012 |
| Drug |
gefitinib/docetaxel |
1 |
2005 |
| Drug |
gefitinib/metformin |
1 |
2013 |
| Drug |
gefitinib/nimotuzumab |
1 |
2011 |
| Drug |
gefitinib/olaparib |
1 |
2011 |
| Drug |
gefitinib/placebo |
1 |
2013 |
| Drug |
gemcitabine / cisplatine |
1 |
2005 |
| Drug |
gemcitabine /carboplatin |
1 |
2011 |
| Drug |
gemcitabine 1200mg |
1 |
2012 |
| Drug |
gemcitabine cisplatin followed by docetaxel |
1 |
2007 |
| Drug |
gemcitabine hcl |
1 |
2006 |
| Drug |
gemcitabine injection |
1 |
2012 |
| Drug |
gemcitabine platinum |
1 |
2014 |
| Drug |
gemcitabine platinum/with erlotinib |
1 |
2014 |
| Drug |
gemcitabine prolonged continuous infusion |
1 |
2006 |
| Drug |
gemcitabine, carboplatin |
1 |
2005 |
| Drug |
gemcitabine, carboplatin, bevacizumab |
1 |
2006 |
| Drug |
gemcitabine, cisplatin |
1 |
2005 |
| Drug |
gemcitabine/cisplatin/gemcitabine/carboplatin |
1 |
2008 |
| Drug |
gemcitabine/eloxatin (gemox) |
1 |
2004 |
| Drug |
gemcitabine/nab-paclitaxel |
1 |
2013 |
| Drug |
gemcitabine/pemetrexed, paclitaxel/gemcitabine |
1 |
2007 |
| Drug |
gemcitabine/with cisplatin |
1 |
2013 |
| Drug |
gemcitabineâ® |
1 |
2016 |
| Genetic |
genetic linkage analysis |
1 |
2012 |
| Drug |
genexol-pm |
1 |
2013 |
| Drug |
genexol-pm/gemcitabine |
1 |
2013 |
| Biological |
gi-4000 |
1 |
2008 |
| Drug |
gilotrif |
1 |
2013 |
| Drug |
glesatinib |
1 |
2016 |
| Drug |
glufosfamide |
1 |
2000 |
| Drug |
gold sodium thiomalate |
1 |
2007 |
| Drug |
gp |
1 |
2012 |
| Drug |
gr-md-02 |
1 |
2015 |
| Drug |
grapiprant |
1 |
2018 |
| Drug |
grapiprant/pembrolizumab |
1 |
2018 |
| Radiation |
group 1: peripherally located tumors |
1 |
2016 |
| Radiation |
group 2: peripherally located chest wall adjacent tumors |
1 |
2016 |
| Radiation |
group 3: centrally located tumors |
1 |
2016 |
| Biological |
gsk 249553 vaccine |
1 |
2006 |
| Drug |
gsk1120212 |
1 |
2011 |
| Drug |
gt103 |
1 |
2020 |
| Biological |
gti-2040 |
1 |
2003 |
| Diagnostic Test |
guardant360 |
1 |
2018 |
| Biological |
gv 1001 telomerase peptide |
1 |
2007 |
| Drug |
hbi-8000 in combination with nivolumab |
1 |
2016 |
| Drug |
hd204 |
1 |
2017 |
| Drug |
hdm201 |
1 |
2016 |
| Drug |
hdregn2810 |
1 |
2018 |
| Biological |
hekt cell |
1 |
2017 |
| Drug |
hemay020 |
1 |
2015 |
| Radiation |
heterogeneously hypofractionated radiotherapy |
1 |
2017 |
| Drug |
hh2710 |
1 |
2019 |
| Biological |
high-activity natural killer |
1 |
2016 |
| Radiation |
high dose chemoradiotherapy |
1 |
2018 |
| Radiation |
high dose radiotherapy |
1 |
2005 |
| Other |
high performance liquid chromatography |
1 |
2008 |
| Radiation |
hippocampal-sparing wbrt |
1 |
2015 |
| Drug |
hki-272 |
1 |
2005 |
| Biological |
hla-a*0201 |
1 |
2010 |
| Biological |
hla-a0201/hla-a0206-restricted urlc10 peptides |
1 |
2010 |
| Biological |
hla-a*0201restricted urlc10 peptides with adjuvant |
1 |
2013 |
| Biological |
hla-a*0206-restricted urlc10 peptides |
1 |
2010 |
| Biological |
hla-a*2402restricted urlc10, cdca1, vegfr1 |
1 |
2009 |
| Biological |
hla-a*2402restricted urlc10, cdca1, vegfr1/vegfr2 |
1 |
2009 |
| Biological |
hla-a*2402restricted urlc10, cdca1,/kif20a peptides |
1 |
2010 |
| Biological |
hla-a*2402restricted urlc10, cdca1,/kif20a peptides with adjuvant |
1 |
2013 |
| Biological |
hla-a*2402restricted urlc10, ttk, vegfr1 |
1 |
2008 |
| Biological |
hla-a*2402restricted urlc10, ttk, vegfr1/vegfr2 |
1 |
2008 |
| Drug |
hlx04, a bevacizumab biosimilar |
1 |
2019 |
| Drug |
hlx10 |
1 |
2019 |
| Drug |
hlx10, an engineered anti-pd-1 antibody |
1 |
2019 |
| Drug |
hmab biwa 4 |
1 |
2014 |
| Drug |
hpph |
1 |
2012 |
| Biological |
hpv vaccine |
1 |
2013 |
| Drug |
hs-10296 |
1 |
2018 |
| Biological |
hsppc-96 |
1 |
2004 |
| Drug |
hycamtin, oral capsules |
1 |
2006 |
| Radiation |
hypofractionated radiation |
1 |
2016 |
| Radiation |
hypofractionated radiation/chemotherapy |
1 |
2016 |
| Radiation |
hypofractionated radiotherapy (hyport) |
1 |
2009 |
| Drug |
i124-nm404 |
1 |
2007 |
| Drug |
ibi305 |
1 |
2019 |
| Drug |
icotinib hydrochloride tablets |
1 |
2019 |
| Drug |
idasanutlin |
1 |
2017 |
| Biological |
idc-g305 |
1 |
2013 |
| Drug |
idelalisib |
1 |
2017 |
| Drug |
ifosfamide, gemcitabine |
1 |
2008 |
| Dietary Supplement |
igen0206 |
1 |
2019 |
| Biological |
ilixadencel |
1 |
2018 |
| Device |
illinois bone marrow aspiration neddle |
1 |
2015 |
| Drug |
ilx651 |
1 |
2004 |
| Biological |
ima201 product |
1 |
2017 |
| Drug |
ima202 product |
1 |
2018 |
| Radiation |
image-guided adaptive radiation therapy |
1 |
2012 |
| Other |
imaging biomarker analysis |
1 |
2007 |
| Behavioral |
imaging studies) |
1 |
2013 |
| Biological |
imc-1121b (ramucirumab) |
1 |
2010 |
| Biological |
imc-a12 (cixutumumab) |
1 |
2009 |
| Drug |
imetelstat |
1 |
2010 |
| Drug |
imetelstat sodium (grn163l) |
1 |
2007 |
| Drug |
imexon |
1 |
2006 |
| Drug |
imiquimod |
1 |
2013 |
| Drug |
immu-132 |
1 |
2012 |
| Drug |
immune checkpoint inhibitors |
1 |
2016 |
| Drug |
immune checkpoint inhibitors/docetaxel |
1 |
2016 |
| Biological |
immune killer cells (ikc) |
1 |
2018 |
| Drug |
immuno-therapeutic agent |
1 |
2017 |
| Other |
immunologic technique |
1 |
2008 |
| Biological |
immunotherapy |
1 |
2016 |
| Biological |
immunotherapy (standard of care) |
1 |
2017 |
| Drug |
imo-2055 |
1 |
2008 |
| Radiation |
imp-288-indium |
1 |
2010 |
| Radiation |
imp-288-lutetium |
1 |
2010 |
| Drug |
imprime pgg |
1 |
2016 |
| Biological |
imprime pgg injection |
1 |
2009 |
| Biological |
imprime pggâ® injection |
1 |
2009 |
| Drug |
inbrx-106 - hexavalent ox40 agonist antibody |
1 |
2019 |
| Drug |
inc280 (capmatinib) |
1 |
2015 |
| Drug |
individualized neoantigen peptides vaccine |
1 |
2020 |
| Drug |
individualized pharmacokinetically driven paclitaxel dosing |
1 |
2011 |
| Drug |
indoximod |
1 |
2015 |
| Drug |
induction chemotherapy |
1 |
2013 |
| Biological |
infliximab |
1 |
2002 |
| Drug |
inhalation of hyperpolarized xenon gas |
1 |
2014 |
| Drug |
iniparib |
1 |
2010 |
| Other |
injection of [18f]-ods2004436 radiotracer |
1 |
2016 |
| Procedure |
injection of 99m-tc-nm-01 |
1 |
2016 |
| Other |
integrated palliative care intervention |
1 |
2009 |
| Radiation |
intensity-modulated radiation therapy (imrt) |
1 |
2017 |
| Radiation |
intensity modulated radiation therapy (imrt) |
1 |
2019 |
| Radiation |
intensity modulated radiotherapy treatment |
1 |
2013 |
| Procedure |
intercostal uniportal vats |
1 |
2017 |
| Drug |
interleukin-2 (il2) |
1 |
2017 |
| Other |
internet-based intervention |
1 |
2011 |
| Other |
intervention arm |
1 |
2013 |
| Drug |
intralesional il-2 |
1 |
2017 |
| Drug |
intravenous (iv) sea-cd40 |
1 |
2015 |
| Procedure |
intubated anesthesia with single-lung mechanical ventilation |
1 |
2018 |
| Drug |
investigational drug |
1 |
2002 |
| Drug |
investigatorâ´s choice of chemotherapy |
1 |
2010 |
| Diagnostic Test |
invision |
1 |
2019 |
| Drug |
ipatasertib |
1 |
2017 |
| Drug |
ipi-504 |
1 |
2011 |
| Drug |
ipi-549 |
1 |
2015 |
| Drug |
ipi 504 |
1 |
2011 |
| Drug |
ipi 504/docetaxel |
1 |
2011 |
| Biological |
ipilimumab 1 mg |
1 |
2013 |
| Biological |
ipilimumab 1 mg/kg |
1 |
2013 |
| Drug |
ipilimumab, 10 mg |
1 |
2010 |
| Drug |
ipilimumab, 3 mg |
1 |
2010 |
| Drug |
ipilimumab/radiation therapy |
1 |
2017 |
| Drug |
irx4204 |
1 |
2016 |
| Drug |
isatuximab sar650984 |
1 |
2017 |
| Drug |
iscar quercus |
1 |
2006 |
| Drug |
isis eif4e rx |
1 |
2010 |
| Drug |
isoquercetin |
1 |
2014 |
| Radiation |
isotoxic hypofractionated group |
1 |
2018 |
| Radiation |
isotoxic hypofractionation |
1 |
2018 |
| Drug |
isovue-200 |
1 |
2016 |
| Drug |
ispinesib |
1 |
2004 |
| Drug |
itraconazole 200 mg |
1 |
2018 |
| Radiation |
itv |
1 |
2012 |
| Drug |
ixabepilone, 32 mg/m^2 |
1 |
2008 |
| Drug |
ixabepilone, 32 mg/m^2 / carboplatin, 5 mg/min/ml |
1 |
2008 |
| Drug |
ixabepilone, 32 mg/m^2 / carboplatin, 6 mg/min/ml |
1 |
2008 |
| Drug |
jin fu kang |
1 |
2005 |
| Drug |
jnj-74699157 |
1 |
2019 |
| Drug |
kanglaite injection |
1 |
2019 |
| Drug |
kanglaite injection/chemotherapy |
1 |
2019 |
| Drug |
karenitecin |
1 |
2001 |
| Drug |
karenitecin (bnp1350) |
1 |
2004 |
| Drug |
keytruda injectable product |
1 |
2019 |
| Genetic |
ki-67 protein expression |
1 |
2009 |
| Biological |
kif20a peptides |
1 |
2010 |
| Biological |
kif20a peptides with adjuvant |
1 |
2013 |
| Drug |
kos-1584 |
1 |
2008 |
| Drug |
l-nmma |
1 |
2017 |
| Drug |
ladiratuzumab vedotin |
1 |
2019 |
| Procedure |
laser ablation |
1 |
2018 |
| placebo |
lazertinib-matching placebo 240 mg |
1 |
2020 |
| Drug |
lazertinib-matching placebo 240 mg/160 mg |
1 |
2020 |
| Drug |
lazertinib 240 mg |
1 |
2020 |
| Drug |
lazertinib 240 mg/160 mg |
1 |
2020 |
| Drug |
lbh589 |
1 |
2007 |
| Drug |
lcl161 |
1 |
2016 |
| Drug |
ldk378(ceritinib) |
1 |
2017 |
| placebo |
lenvatinib matched placebo |
1 |
2012 |
| Other |
less frequent surveillance strategy |
1 |
2015 |
| Dietary Supplement |
leu |
1 |
2010 |
| Dietary Supplement |
leu vs total aa |
1 |
2010 |
| Drug |
leucovorin |
1 |
2013 |
| Drug |
leucovorin calcium |
1 |
2006 |
| Behavioral |
lifestyle counseling |
1 |
2014 |
| Behavioral |
light physical activity 1 |
1 |
2018 |
| Behavioral |
light physical activity 2 |
1 |
2018 |
| Drug |
linagliptin |
1 |
2017 |
| Dietary Supplement |
lindera obtusiloba extract |
1 |
2020 |
| Drug |
linifanib |
1 |
2010 |
| Combination Product |
litt |
1 |
2019 |
| Combination Product |
litt / pembrolizumab |
1 |
2019 |
| Drug |
lmb-100 |
1 |
2019 |
| Radiation |
local definitive radiotherapy |
1 |
2017 |
| Radiation |
local radiation therapy |
1 |
2019 |
| Drug |
lomustine |
1 |
2006 |
| Drug |
loperamide |
1 |
2013 |
| Genetic |
loss of heterozygosity analysis |
1 |
2003 |
| Radiation |
low-let cobalt-60 gamma ray therapy |
1 |
1999 |
| Drug |
loxo-292 (selpercatinib) |
1 |
2017 |
| Diagnostic Test |
lsi alk break apart dna fish test |
1 |
2019 |
| Drug |
ltt462 |
1 |
2016 |
| Biological |
lucanixâ„¢ |
1 |
2008 |
| Procedure |
lung surgery |
1 |
2015 |
| Drug |
lurbinectedin (pm01183) |
1 |
2013 |
| Drug |
ly01008 |
1 |
2018 |
| Drug |
ly2181308 |
1 |
2010 |
| Drug |
ly293111 |
1 |
2003 |
| Drug |
ly3023414 |
1 |
2014 |
| Drug |
ly573636-sodium |
1 |
2006 |
| Drug |
lyc-55716 |
1 |
2018 |
| Procedure |
lymphadenectomy |
1 |
2008 |
| Drug |
m2 d1,8, 21, 28 |
1 |
2012 |
| Drug |
m2) iv (in the vein) on day 1 |
1 |
2012 |
| Drug |
m2) iv (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles |
1 |
2012 |
| Drug |
m200 (volociximab), carboplatin, paclitaxel |
1 |
2008 |
| Drug |
m200 (volociximab), carboplatin, paclitaxel, bevacizumab |
1 |
2008 |
| Drug |
m2es |
1 |
2010 |
| Drug |
mac-321 |
1 |
2003 |
| Drug |
maintenance chemotherapy |
1 |
2014 |
| Procedure |
management |
1 |
1999 |
| Biological |
mapatumumab |
1 |
2007 |
| Drug |
marimastat |
1 |
1999 |
| Other |
mass spectrometry |
1 |
2007 |
| placebo |
matching placebo |
1 |
2020 |
| Drug |
matuzumab |
1 |
2005 |
| Drug |
mb02 (bevacizumab biosimilar drug) |
1 |
2017 |
| Biological |
mdx-1106 |
1 |
2007 |
| Drug |
medi-575 |
1 |
2010 |
| Drug |
medi4736 (anti-pd-l1) |
1 |
2015 |
| Biological |
medi4736 (durvalumab) |
1 |
2015 |
| Biological |
medi4736 (durvalumab)/tremelimumab |
1 |
2015 |
| Drug |
medi5752 |
1 |
2018 |
| Drug |
medi7247 |
1 |
2018 |
| Biological |
medi9447 |
1 |
2017 |
| Procedure |
mediastinoscopy |
1 |
2010 |
| Other |
medical history data collection |
1 |
2019 |
| Behavioral |
medical outcomes study social support survey |
1 |
2015 |
| Drug |
megf0444a |
1 |
2011 |
| Drug |
mek162 |
1 |
2013 |
| Drug |
merestinib |
1 |
2016 |
| Diagnostic Test |
mesothelin expression |
1 |
2019 |
| Other |
met analysis on tissue |
1 |
2012 |
| Other |
met analysis on tissue/blood |
1 |
2012 |
| Drug |
methotrexate |
1 |
2018 |
| Drug |
methoxy polyethylene glycol-epoetin beta [mircera] |
1 |
2006 |
| Drug |
metmab |
1 |
2009 |
| Drug |
metronidazole actavis |
1 |
2008 |
| Biological |
mg1-magea3 |
1 |
2016 |
| Biological |
mga012 |
1 |
2015 |
| Biological |
mga271 |
1 |
2011 |
| Drug |
mgcd265 |
1 |
2015 |
| Genetic |
microarray analysis |
1 |
2003 |
| Procedure |
microwave ablation |
1 |
2018 |
| Radiation |
mid-position radiation strategy |
1 |
2012 |
| Drug |
mifepristone/eribulin in combination |
1 |
2013 |
| Drug |
mil60 |
1 |
2017 |
| Biological |
milsâ„¢ - nsclc |
1 |
2019 |
| Device |
miso pet scan |
1 |
2015 |
| Drug |
mistletoe extract |
1 |
2007 |
| Other |
mitochondria-targeted system therapy |
1 |
2019 |
| Other |
mitochondria-targeted system therapy/with radiofrequency ablation |
1 |
2019 |
| Drug |
mitomycin |
1 |
2005 |
| Drug |
mitomycin c |
1 |
1999 |
| Drug |
mk-1308 |
1 |
2018 |
| Drug |
mk-3475 (phase i) |
1 |
2015 |
| Drug |
mk-3475 (phase ii) |
1 |
2015 |
| Biological |
mk-4280 |
1 |
2018 |
| Biological |
mk-4830 |
1 |
2019 |
| Biological |
mk-5890 |
1 |
2019 |
| Biological |
mk-7684 |
1 |
2019 |
| Drug |
mkc-1 |
1 |
2006 |
| Drug |
mocetinostat |
1 |
2016 |
| Drug |
modafinil |
1 |
2009 |
| Behavioral |
modified medical research council |
1 |
2015 |
| Other |
modified medical research council dyspnea patient reported outcomes |
1 |
2020 |
| Biological |
modified vaccinia virus ankara vaccine expressing p53 |
1 |
2015 |
| Device |
modulated electro-hyperthermia (meht) |
1 |
2016 |
| Biological |
mogamulizumab |
1 |
2015 |
| Procedure |
molecular profiling |
1 |
2011 |
| Drug |
monalizumab (iph2201 |
1 |
2019 |
| Biological |
monoclonal antibody 11d10 anti-idiotype vaccine |
1 |
2000 |
| Biological |
monoclonal antibody 3h1 anti-idiotype vaccine |
1 |
2000 |
| Drug |
monotherapy (gemcitabine |
1 |
2006 |
| Drug |
monotherapy (gemcitabine/vinorelbine) |
1 |
2006 |
| Biological |
montanide isa 51 vaccine |
1 |
2016 |
| Drug |
morab-009 |
1 |
2006 |
| Other |
more frequent surveillance strategy |
1 |
2015 |
| Drug |
motesanib diphosphate |
1 |
2004 |
| Drug |
motexafin gadolinium injection |
1 |
2005 |
| Device |
move for surgery preconditioning program using a wearable activity tracker (fitbit) intervention group |
1 |
2018 |
| Radiation |
mri |
1 |
2008 |
| Drug |
mtig7192a |
1 |
2018 |
| Radiation |
multiple-fraction stereotactic body radiation therapy (sbrt) |
1 |
2009 |
| Biological |
mutant p53 peptide pulsed dendritic cell vaccine |
1 |
2001 |
| Biological |
mva-muc1-il2 |
1 |
2006 |
| Biological |
mycobacterium w. |
1 |
2008 |
| Drug |
n-803 |
1 |
2018 |
| Drug |
n-803 / pembrolizumab |
1 |
2018 |
| Drug |
nab-paclitaxel 100 mg |
1 |
2013 |
| Drug |
nab-paclitaxel 100 mg/m^2 |
1 |
2013 |
| Drug |
nab-paclitaxel iv |
1 |
2014 |
| Drug |
nab-paclitaxel/carboplatin |
1 |
2018 |
| Drug |
nadaplatin |
1 |
2015 |
| Drug |
nadaplatin/pemetrexed |
1 |
2015 |
| Drug |
nafulizumab |
1 |
2020 |
| Drug |
naloxegol |
1 |
2017 |
| Drug |
naquotinib |
1 |
2014 |
| Biological |
natural killer |
1 |
2017 |
| Biological |
natural killer t cell |
1 |
2017 |
| Biological |
natural killer/natural killer t cell |
1 |
2017 |
| Procedure |
nausea |
1 |
1999 |
| Procedure |
nausea/vomiting therapy |
1 |
1999 |
| Drug |
navarixin |
1 |
2018 |
| Drug |
navelbine |
1 |
2005 |
| Drug |
navitoclax |
1 |
2015 |
| Drug |
nb-paclitaxel |
1 |
2019 |
| Drug |
nc318 |
1 |
2018 |
| Drug |
nelfinavir mesylate |
1 |
2007 |
| Drug |
neoadjuvant chemotherapy (taxol |
1 |
2009 |
| Drug |
neoadjuvant chemotherapy (taxol/carboplatin) |
1 |
2009 |
| Drug |
neoadjuvant erlotinib therapy |
1 |
2008 |
| Drug |
neoadjuvant gemcitabine |
1 |
2008 |
| Drug |
neoadjuvant gemcitabine/carboplatin therapy |
1 |
2008 |
| Radiation |
neoadjuvant stereotactic body radiation (sbrt) |
1 |
2015 |
| Drug |
neratinib |
1 |
2013 |
| Drug |
neulastaâ® (pegfilgrastim) |
1 |
2005 |
| Drug |
nexavar (sorafenib, bay43-9006) |
1 |
2010 |
| Drug |
ngr-htnf |
1 |
2009 |
| Drug |
nicotinamide |
1 |
2015 |
| Drug |
nicotine replacement therapy |
1 |
2011 |
| Drug |
nintedanib (bibf1120) |
1 |
2008 |
| Drug |
nivolumab / ipilimumab |
1 |
2017 |
| Drug |
nivolumab / plinabulin |
1 |
2016 |
| Drug |
nivolumab 360 mg |
1 |
2017 |
| Drug |
nivolumab, ipilimumab |
1 |
2017 |
| Drug |
nivolumab, pembrolizumab |
1 |
2018 |
| Combination Product |
nk cell |
1 |
2019 |
| Combination Product |
nk cell/pd-1 antibody |
1 |
2019 |
| Biological |
nk cells |
1 |
2008 |
| Drug |
nktr-214 |
1 |
2017 |
| Diagnostic Test |
no daily chest xray |
1 |
2018 |
| Drug |
no local definitive radiotherapy |
1 |
2017 |
| Other |
no metformin |
1 |
2019 |
| Radiation |
no personalized dose redistribution |
1 |
2015 |
| Other |
non-active moisturizing cream |
1 |
2008 |
| Radiation |
non-daily stereotactic body radiotherapy |
1 |
2018 |
| Other |
non-investigational platinum-based doublet chemotherapy |
1 |
2015 |
| Radiation |
non-surgical lat |
1 |
2019 |
| Other |
none, standard chemotherapy only |
1 |
2014 |
| Drug |
nov-002 injection in combination with carboplatin vs. paclitaxel |
1 |
2006 |
| Drug |
nov-002 injection in combination with carboplatin vs. paclitaxel/carboplatin |
1 |
2006 |
| Device |
novottf-100m device |
1 |
2016 |
| Drug |
npi-0052 (marizomib) |
1 |
2008 |
| Drug |
npi-0052 (marizomib) / vorinostat |
1 |
2008 |
| Drug |
npi-2358 |
1 |
2008 |
| Drug |
npi-2358 / docetaxel |
1 |
2008 |
| Drug |
ocz103-os |
1 |
2013 |
| Drug |
od for 12 weeks |
1 |
2007 |
| Drug |
ogx-427 |
1 |
2013 |
| Biological |
olaratumab |
1 |
2009 |
| Drug |
oleclumab (medi9447) |
1 |
2019 |
| Drug |
olmutinib |
1 |
2017 |
| Drug |
omaveloxolone |
1 |
2013 |
| Drug |
ombrabulin (ave8062) |
1 |
2010 |
| Drug |
onalespib lactate |
1 |
2015 |
| Drug |
onartuzumab (metmab) |
1 |
2011 |
| Drug |
onartuzumab [metmab] |
1 |
2014 |
| Diagnostic Test |
oncomine |
1 |
2019 |
| Dietary Supplement |
oncoxinâ® |
1 |
2018 |
| Dietary Supplement |
ons from the start of radiotherapy |
1 |
2018 |
| Dietary Supplement |
ons from the time of grade 2 radiation esophagitis |
1 |
2018 |
| Drug |
opdivo |
1 |
2017 |
| Procedure |
or of all oligometastases |
1 |
2019 |
| Drug |
oral decitabine |
1 |
2016 |
| Drug |
oral taxane |
1 |
2005 |
| Drug |
oral vinorelbine/cisplatin with concomitant radiotherapy 66 gy (total dose) |
1 |
2008 |
| Drug |
ose2101 |
1 |
2016 |
| Drug |
osi-774 (tarceva) |
1 |
2005 |
| Drug |
osi-774: erlotinib, tarcevatm |
1 |
2007 |
| Drug |
osimertinib 80 mg [tagrisso] |
1 |
2017 |
| Drug |
osimertinib 80mg |
1 |
2018 |
| Drug |
osimertinib 80mg/40mg |
1 |
2018 |
| Drug |
osimertininb tablet dosing |
1 |
2016 |
| Drug |
oxaliplatin, gemcitabine, bevacizumab |
1 |
2005 |
| Drug |
oxaliplatine |
1 |
2005 |
| Drug |
oxaliplatine / gemcitabine / vinorelbine |
1 |
2005 |
| Drug |
pabolizumab |
1 |
2020 |
| Drug |
paclitaxel-carboplatin |
1 |
2008 |
| Drug |
paclitaxel (cp) |
1 |
2004 |
| Drug |
paclitaxel (genexolâ®) |
1 |
2009 |
| Drug |
paclitaxel (taxane) |
1 |
2005 |
| Drug |
paclitaxel (taxol) |
1 |
2008 |
| Drug |
paclitaxel / carboplatine |
1 |
2005 |
| Drug |
paclitaxel 200mg |
1 |
2017 |
| Drug |
paclitaxel 200mg/m2 |
1 |
2017 |
| Drug |
paclitaxel 45 mg |
1 |
2018 |
| Drug |
paclitaxel 45 mg/m^2 |
1 |
2018 |
| Drug |
paclitaxel dosing according to smpc |
1 |
2011 |
| Drug |
paclitaxel liposome |
1 |
2016 |
| Drug |
paclitaxel loaded polymeric micelle (genexol-pmâ®) |
1 |
2009 |
| Drug |
paclitaxel micelles for injection |
1 |
2016 |
| Drug |
paclitaxel poliglumex, pemetrexed |
1 |
2007 |
| Drug |
paclitaxel, 200 mg |
1 |
2008 |
| Drug |
paclitaxel, 200 mg/m^2 |
1 |
2008 |
| Drug |
paclitaxel, carboplatin |
1 |
2008 |
| Drug |
paclitaxel, carboplatin/bevacizumab,erlotinib |
1 |
2008 |
| Drug |
paclitaxel, cisplatin, carboplatin |
1 |
2013 |
| Drug |
paclitaxel, vinorelbine, cisplatin |
1 |
2005 |
| Drug |
paclitaxel/carboplatin/gefitinib |
1 |
2010 |
| Drug |
paclitaxel/cisplatin |
1 |
2008 |
| Drug |
paclitaxel/docetaxel/carboplatin/cisplatin |
1 |
2013 |
| Procedure |
pain therapy |
1 |
1999 |
| Drug |
palifermin |
1 |
2004 |
| Other |
palliative radiotherapy |
1 |
2009 |
| Other |
palliative radiotherapy/chemotherapy |
1 |
2009 |
| Other |
palliative therapy |
1 |
2014 |
| Procedure |
palliative thoracic radiotherapy |
1 |
2005 |
| Drug |
panobinostat |
1 |
2016 |
| Drug |
panobinostat (lbh589), sorafenib |
1 |
2009 |
| Drug |
panobinostat, cisplatin, pemetrexed |
1 |
2011 |
| Drug |
papaverine hydrochloride |
1 |
2019 |
| Drug |
para-toluenesulfonamide |
1 |
2018 |
| Procedure |
parametric imaging |
1 |
2016 |
| Drug |
part a - azd9291 in combination with azd6094 |
1 |
2014 |
| Drug |
part a - azd9291 in combination with continuous selumetinib (asian subjects) |
1 |
2014 |
| Drug |
part a - azd9291 in combination with continuous selumetinib (non-asian subjects) |
1 |
2014 |
| Drug |
part a - azd9291 in combination with intermittent selumetinib |
1 |
2014 |
| Drug |
part a - azd9291 in combination with medi4736 |
1 |
2014 |
| Drug |
part a: azd8186 monotherapy |
1 |
2013 |
| Drug |
part b - azd9291 in combination with azd6094 |
1 |
2014 |
| Drug |
part b - azd9291 in combination with medi4736 |
1 |
2014 |
| Drug |
part b - azd9291 in combination with selumetinib |
1 |
2014 |
| Drug |
part b: azd8186 monotherapy |
1 |
2013 |
| Drug |
part c - azd6094 monotherapy (japan only) |
1 |
2014 |
| Drug |
part c - azd9291 in combination with azd6094 (japan only) |
1 |
2014 |
| Drug |
part c1: abiraterone acetate combination with azd8186 |
1 |
2013 |
| Drug |
part c2: abiraterone acetate combination with azd8186 |
1 |
2013 |
| Drug |
part d - azd9291 in combination with azd6094 |
1 |
2014 |
| Drug |
part d1: azd2014 combination with azd8186 |
1 |
2013 |
| Drug |
part d2 azd2014 combination with azd8186 |
1 |
2013 |
| Behavioral |
patient navigation |
1 |
2016 |
| Drug |
pazopanib (gw786034) |
1 |
2008 |
| Drug |
pazopanib/pemetrexed |
1 |
2009 |
| Drug |
pbf-1129 |
1 |
2017 |
| Drug |
pbf-509_160 mg |
1 |
2015 |
| Drug |
pbf-509_320 mg |
1 |
2015 |
| Drug |
pbf-509_640 mg |
1 |
2015 |
| Drug |
pbf-509_80 mg |
1 |
2015 |
| Drug |
pd-0325901 |
1 |
2013 |
| Combination Product |
pd-1 antibody |
1 |
2019 |
| Biological |
pd-1 knockout |
1 |
2018 |
| Other |
pd-1 knockout t cells |
1 |
2016 |
| Drug |
pd-1 mab |
1 |
2018 |
| Other |
pd-l1 positive vs pd-l1 negative nsclc patients |
1 |
2018 |
| Drug |
pd0332991 |
1 |
2011 |
| Biological |
pdc*lung01 |
1 |
2019 |
| Drug |
pdr001)_immuno naã¯ve |
1 |
2015 |
| Drug |
pdr001)_immuno treated |
1 |
2015 |
| Other |
pe |
1 |
2011 |
| Drug |
pegilodecakin |
1 |
2013 |
| Drug |
pegylated g-csf |
1 |
2013 |
| Drug |
pegylated irinotecan |
1 |
2014 |
| Drug |
pegylated recombinant human endostatin(peg-endo) |
1 |
2020 |
| Biological |
pembrolizumab (keytrudaâ®) |
1 |
2019 |
| Biological |
pembrolizumab 10 mg |
1 |
2013 |
| Biological |
pembrolizumab 10 mg/kg |
1 |
2013 |
| Drug |
pembrolizumab 100 mg i.v single dose |
1 |
2016 |
| Drug |
pembrolizumab 200 mg iv single dose |
1 |
2016 |
| Drug |
pembrolizumab 200 mg iv twice interval 21 days |
1 |
2016 |
| Drug |
pembrolizumab 200 mg iv twice interval 21d,surgery after 10d |
1 |
2016 |
| Drug |
pembrolizumab/bevacizumab |
1 |
2016 |
| Drug |
pembrolizumab/chemotherapy |
1 |
2018 |
| Drug |
pembrort |
1 |
2018 |
| Drug |
pemetrexed - after protocol amendment |
1 |
2006 |
| Drug |
pemetrexed - before protocol amendment |
1 |
2006 |
| Drug |
pemetrexed (alimta) in combination with gemcitabine (gemzar) |
1 |
2002 |
| Drug |
pemetrexed 1000 mg |
1 |
2005 |
| Drug |
pemetrexed 1000 mg/m2 |
1 |
2005 |
| Drug |
pemetrexed 500 mg/m2 |
1 |
2005 |
| Drug |
pemetrexed disodium f injection |
1 |
2020 |
| Drug |
pemetrexed phase 1 |
1 |
2007 |
| Drug |
pemetrexed phase 2 |
1 |
2007 |
| Drug |
pemetrexed regimen) |
1 |
2016 |
| Drug |
pemetrexed, docetaxel |
1 |
2011 |
| Drug |
pemetrexed, docetaxel/gemcitabine |
1 |
2011 |
| Drug |
pemetrexed, paclitaxel |
1 |
2007 |
| Drug |
pemetrexed/ carboplatin |
1 |
2018 |
| Drug |
pemetrexed/ cisplatin |
1 |
2018 |
| Drug |
pemetrexed/cisplatin intercalating gefitinib |
1 |
2017 |
| Biological |
pemetrexed/donor-derived nk cell infusion |
1 |
2017 |
| Drug |
pemetrexed/gemcitabine/bevacizumab |
1 |
2007 |
| Drug |
pemetrexed/reolysin (and safety run-in) |
1 |
2012 |
| Drug |
pemetrexedâ® |
1 |
2016 |
| Drug |
pentoxifylline |
1 |
2013 |
| Drug |
perifosine |
1 |
2006 |
| Radiation |
peripherally located lung tumor |
1 |
2009 |
| Radiation |
personalized dose redistribution |
1 |
2015 |
| Behavioral |
personalized exercise program |
1 |
2017 |
| Drug |
pertuzumab / trastuzumab / docetaxel |
1 |
2019 |
| Combination Product |
pet-based, dose-painted, accelerated chemoradiotherapy |
1 |
2018 |
| Diagnostic Test |
pet-mri |
1 |
2018 |
| Procedure |
pet diagnostic imaging |
1 |
2005 |
| Procedure |
pet imaging |
1 |
2005 |
| Diagnostic Test |
pet scan |
1 |
2018 |
| Procedure |
pet scan use in radiotherapy planning |
1 |
2000 |
| Diagnostic Test |
pet/ct scans |
1 |
2018 |
| Drug |
pevonedistat |
1 |
2019 |
| Drug |
pf-05082566 |
1 |
2011 |
| Drug |
pf-06747775 |
1 |
2015 |
| Drug |
pf-06804103 |
1 |
2017 |
| Biological |
pf-06936308 |
1 |
2018 |
| Drug |
pf-3512676 / erlotinib |
1 |
2006 |
| Procedure |
pharmacokinetic sampling |
1 |
2014 |
| Procedure |
pharmacokinetic sampling - rifampicin |
1 |
2014 |
| Procedure |
pharmacokinetic sampling - rosuvastatin |
1 |
2014 |
| Procedure |
pharmacokinetic sampling - simvastatin |
1 |
2014 |
| Radiation |
photons |
1 |
2014 |
| Procedure |
physical therapy |
1 |
2019 |
| Procedure |
physician does not receive the results |
1 |
2011 |
| Procedure |
physician receives qol results |
1 |
2011 |
| Other |
physiological saline |
1 |
2012 |
| Drug |
pi3k inhibitor bkm120 |
1 |
2012 |
| Drug |
pictilisib |
1 |
2011 |
| Drug |
pilimumab |
1 |
2015 |
| Drug |
pirotinib |
1 |
2018 |
| Drug |
pivanex |
1 |
2003 |
| placebo |
placebo (0.9 % saline) |
1 |
2009 |
| placebo |
placebo (for bavituximab) |
1 |
2013 |
| placebo |
placebo (for ramucirumab) |
1 |
2010 |
| placebo |
placebo ast2818 80mg |
1 |
2018 |
| Drug |
placebo ast2818 80mg//40 mg |
1 |
2018 |
| Drug |
placebo azd9291 80 mg/ 40 mg |
1 |
2014 |
| Drug |
placebo azd9291 80 mg/40 mg |
1 |
2015 |
| placebo |
placebo erlotinib |
1 |
2011 |
| placebo |
placebo erlotinib 150 |
1 |
2014 |
| Drug |
placebo erlotinib 150/100mg |
1 |
2014 |
| placebo |
placebo for abt-869 |
1 |
2008 |
| placebo |
placebo for ipilimumab |
1 |
2017 |
| placebo |
placebo for lenvatinib |
1 |
2019 |
| placebo |
placebo for veliparib |
1 |
2014 |
| placebo |
placebo granules |
1 |
2016 |
| placebo |
placebo matching lenvatinib |
1 |
2019 |
| placebo |
placebo of aprepitant |
1 |
2015 |
| placebo |
placebo of desloratadine |
1 |
2015 |
| placebo |
placebo osimertinib 80mg |
1 |
2018 |
| Drug |
placebo osimertinib 80mg/40mg |
1 |
2018 |
| placebo |
placebo pf00299804 |
1 |
2011 |
| placebo |
placebo tablet |
1 |
2019 |
| placebo |
placebo tablets |
1 |
2008 |
| placebo |
placebo to bibf 1120 es |
1 |
2014 |
| placebo |
placebo to denosumab |
1 |
2013 |
| placebo |
placebo to match zd6474, vandetanib |
1 |
2008 |
| placebo |
placebo to zoledronic acid |
1 |
2013 |
| Drug |
placebo/chemotherapy |
1 |
2018 |
| placebo |
placebo1 |
1 |
2019 |
| placebo |
placebo2 |
1 |
2019 |
| Drug |
platinum-based agent |
1 |
2007 |
| Drug |
platinum-based doublet chemotherapy |
1 |
2009 |
| Drug |
platinum-based two drug chemotherapy (cisplatin |
1 |
2016 |
| Drug |
platinum-based two drug chemotherapy (cisplatin/carboplatin / vinorelbine/cisplatin/carboplatin / pemetrexed regimen) |
1 |
2016 |
| Drug |
platinum / gemcitabine |
1 |
2005 |
| Drug |
platinum based chemotherapy |
1 |
2018 |
| Drug |
platinum chemotherapy (cisplatin |
1 |
2009 |
| Drug |
platinum chemotherapy (cisplatin/carboplatin) |
1 |
2009 |
| Drug |
plb1003 |
1 |
2017 |
| Drug |
plinabulin |
1 |
2016 |
| Drug |
plinabulin (dp) |
1 |
2015 |
| Biological |
polyiclc |
1 |
2012 |
| Genetic |
polymorphism analysis |
1 |
2012 |
| Drug |
ponatinib 15 mg |
1 |
2018 |
| Drug |
ponatinib 30 mg |
1 |
2018 |
| Radiation |
port-first |
1 |
2016 |
| Radiation |
port-last |
1 |
2016 |
| Procedure |
positron emission tomography (pet) |
1 |
2018 |
| Drug |
post-medication for docetaxel) |
1 |
2007 |
| Diagnostic Test |
post-sabr biopsy |
1 |
2018 |
| Drug |
poziotinib once daily dosing |
1 |
2020 |
| Drug |
poziotinib once daily dosing/twice daily dosing as determined in phase 1 |
1 |
2020 |
| Drug |
poziotinib twice daily dosing |
1 |
2020 |
| Drug |
pralsetinib |
1 |
2020 |
| Drug |
pralsetinib (blu-667) |
1 |
2017 |
| Drug |
pre-surgical docetaxel |
1 |
2005 |
| Drug |
pre-surgical docetaxel/cisplatin/adjuvant bevacizumab |
1 |
2005 |
| Drug |
pre-surgical treatment with bevacizumab |
1 |
2005 |
| Drug |
pre-surgical treatment with bevacizumab/chemotherapy |
1 |
2005 |
| Dietary Supplement |
prealbumin goal-based ons |
1 |
2018 |
| Drug |
premetrexed (alimta) |
1 |
2006 |
| Other |
preoperative pulmonary rehabilitation |
1 |
2019 |
| Radiation |
preoperative radiation |
1 |
2014 |
| Procedure |
preoperative radiochemotherapy |
1 |
2005 |
| Procedure |
preservation of the inferior pulmonary ligament |
1 |
2019 |
| Other |
preventive intervention |
1 |
2016 |
| Drug |
prexasertib |
1 |
2010 |
| Drug |
prinomastat |
1 |
2000 |
| Drug |
pro95780 |
1 |
2007 |
| Drug |
probiotic |
1 |
2011 |
| Drug |
prolonged continuous infusion gemcitabine |
1 |
2006 |
| Radiation |
prophylactic cranial irradiation |
1 |
2011 |
| Genetic |
proteomic profiling |
1 |
2007 |
| Radiation |
proton beam radiation therapy (pbt) |
1 |
2014 |
| Device |
proton beam therapy |
1 |
2017 |
| Radiation |
proton beam therapy rt |
1 |
2019 |
| Drug |
ptk787 |
1 |
2005 |
| Drug |
ptk787/ zk 222584 |
1 |
2005 |
| Drug |
px-866 |
1 |
2010 |
| Drug |
pyrotinib maleate |
1 |
2018 |
| Device |
q spect |
1 |
2015 |
| Biological |
qbkpn ssi |
1 |
2014 |
| Drug |
qbm076 |
1 |
2016 |
| Behavioral |
qigong |
1 |
2016 |
| Drug |
ql1101 |
1 |
2017 |
| Other |
qlq-c30 global health |
1 |
2020 |
| Other |
qlq-c30 global health/quality of life questionnaire |
1 |
2020 |
| Other |
quality of life questionnaire |
1 |
2020 |
| Other |
quality of life questionnaire, lung cancer-specific (qlq-lc13) |
1 |
2020 |
| Drug |
quinacrine dihydrochloride - escalation dose |
1 |
2013 |
| Drug |
quinacrine dihydrochloride - extension dose |
1 |
2013 |
| Drug |
quisinostat |
1 |
2015 |
| Biological |
racotumomab |
1 |
2010 |
| Procedure |
radiation treatment |
1 |
2005 |
| Radiation |
radiation with concurrent chemotherapy |
1 |
2013 |
| Radiation |
radical radiotherapy - definitive local treatment. |
1 |
2019 |
| Radiation |
radical radiotherapy (conventional rt |
1 |
2015 |
| Radiation |
radical radiotherapy (conventional rt/sabr) |
1 |
2015 |
| Radiation |
radiochemotherapy 1 |
1 |
2017 |
| Radiation |
radiochemotherapy 2 |
1 |
2017 |
| Radiation |
radiochemotherapy 3 |
1 |
2017 |
| Radiation |
radiochemotherapy 4 |
1 |
2017 |
| Radiation |
radiochemotherapy 5 |
1 |
2017 |
| Radiation |
radiochemotherapy 6 |
1 |
2017 |
| Radiation |
radiochemotherapy 7 |
1 |
2017 |
| Procedure |
radiological arm |
1 |
2005 |
| Procedure |
radionuclide imaging |
1 |
2008 |
| Radiation |
radiosurgery |
1 |
2016 |
| Radiation |
radiotherapy (imrt |
1 |
2014 |
| Radiation |
radiotherapy (imrt/3-d crt) |
1 |
2014 |
| Radiation |
radiotherapy (sabr) |
1 |
2017 |
| Radiation |
radiotherapy group |
1 |
2018 |
| Drug |
radiotherapy) |
1 |
2008 |
| Other |
radiotherapy/concurrent chemo-therapy |
1 |
2010 |
| Drug |
radium-223 dichloride (xofigo, bay 88-8223) |
1 |
2019 |
| Drug |
rapamycin (drug will be held) |
1 |
2007 |
| Other |
rapid on-site evaluation |
1 |
2013 |
| Drug |
rc48 |
1 |
2020 |
| Device |
real-time position transponder beacons |
1 |
2017 |
| Other |
real time registry |
1 |
2012 |
| Other |
real time registry/data feedback only |
1 |
2012 |
| Drug |
rebimastat |
1 |
2000 |
| Biological |
recombinant fowlpox-cea(6d) |
1 |
2004 |
| Biological |
recombinant fowlpox-cea(6d)/tricom vaccine |
1 |
2004 |
| Biological |
recombinant fowlpox gm-csf vaccine adjuvant |
1 |
2004 |
| Drug |
recombinant human angiostatin protein |
1 |
2002 |
| Biological |
recombinant human egf-rp64k |
1 |
2016 |
| Biological |
recombinant human egf-rp64k/montanide isa 51 vaccine |
1 |
2016 |
| Drug |
recombinant human erythropoietin (rhuepo) |
1 |
2005 |
| Biological |
recombinant human interleukin-15 |
1 |
2012 |
| Biological |
recombinant interleukin-12 |
1 |
1999 |
| Biological |
recombinant prame protein |
1 |
2013 |
| Biological |
recombinant prame protein/with the as15 adjuvant system gsk2302032a |
1 |
2013 |
| Biological |
recombinant vaccinia-cea(6d)-tricom vaccine |
1 |
2004 |
| Drug |
regn2810/ipi |
1 |
2018 |
| Drug |
regn5093 |
1 |
2019 |
| Other |
regular diet |
1 |
2018 |
| Biological |
relatlimab |
1 |
2016 |
| Drug |
relatlimab 10 mg |
1 |
2019 |
| Drug |
relatlimab 10 mg/ml intravenous solution |
1 |
2019 |
| Procedure |
relaxation therapy |
1 |
2019 |
| Drug |
reolysin |
1 |
2012 |
| Drug |
reolysin (and safety run-in) |
1 |
2012 |
| Biological |
reolysinâ® |
1 |
2009 |
| Radiation |
response-driven adaptive radiation therapy |
1 |
2015 |
| Genetic |
reverse transcriptase-polymerase chain reaction |
1 |
2006 |
| Device |
rf ablation (rita medical systems model 1500x) |
1 |
2008 |
| Drug |
rg1507 |
1 |
2008 |
| Drug |
rh-endostatin |
1 |
2013 |
| Drug |
rhenium (re 188 p2045, bay86-5284) |
1 |
2004 |
| Drug |
rhuph20 |
1 |
2018 |
| Drug |
rifampicin |
1 |
2014 |
| Drug |
rifampin |
1 |
2007 |
| Drug |
rituximab |
1 |
2011 |
| Drug |
ro4929097 |
1 |
2010 |
| Drug |
ro5083945 |
1 |
2010 |
| Drug |
ro5490258 |
1 |
2011 |
| Drug |
ro6958688 |
1 |
2017 |
| Drug |
ro7198457 |
1 |
2020 |
| Drug |
rofecoxib |
1 |
2006 |
| Drug |
rogaratinib |
1 |
2018 |
| Drug |
romidepsin |
1 |
2011 |
| Diagnostic Test |
ros1 ihc |
1 |
2019 |
| Drug |
rosuvastatin |
1 |
2014 |
| Drug |
rp2d (pbf-509 |
1 |
2015 |
| Drug |
rp2d (pbf-509/pdr001)_immuno naã¯ve |
1 |
2015 |
| Drug |
rrx-001 |
1 |
2015 |
| Drug |
rsifn-co |
1 |
2015 |
| Drug |
rucaparib |
1 |
2019 |
| Drug |
rxdx-105 |
1 |
2018 |
| Drug |
s-3304 |
1 |
2004 |
| Drug |
s-588410 |
1 |
2015 |
| Drug |
s-8184 paclitaxel injectable emulsion |
1 |
2002 |
| Radiation |
sabr) |
1 |
2015 |
| Drug |
saf-189s |
1 |
2020 |
| Drug |
sagopilone (bay86-5302, zk 219477) |
1 |
2005 |
| Other |
saline |
1 |
2009 |
| Drug |
salirasib |
1 |
2007 |
| Other |
saliva |
1 |
2019 |
| Drug |
sapanisertib |
1 |
2015 |
| Drug |
saracatinib |
1 |
2008 |
| Biological |
sargramostim |
1 |
2000 |
| Drug |
satraplatin |
1 |
2006 |
| Drug |
satraplatin in combination with paclitaxel |
1 |
2005 |
| Drug |
sb8 |
1 |
2016 |
| Radiation |
sbrt 40.0 gy |
1 |
2008 |
| Radiation |
sbrt 42.5 gy |
1 |
2008 |
| Radiation |
sbrt 45.0 gy |
1 |
2008 |
| Radiation |
sbrt 47.5 gy |
1 |
2008 |
| Radiation |
sbrt 50.0 gy |
1 |
2008 |
| Radiation |
sbrt 52.5 gy |
1 |
2008 |
| Radiation |
sbrt 55.0 gy |
1 |
2008 |
| Radiation |
sbrt 57.5 gy |
1 |
2008 |
| Radiation |
sbrt 60.0 gy |
1 |
2008 |
| Radiation |
sbrt with protons |
1 |
2014 |
| Radiation |
sbrt with protons/photons |
1 |
2014 |
| Radiation |
sbrt/tki |
1 |
2018 |
| Procedure |
scannographic arm |
1 |
2005 |
| Drug |
sch 727965 |
1 |
2008 |
| Drug |
screening platform |
1 |
2019 |
| Drug |
sct-i10 |
1 |
2019 |
| Drug |
sdregn2810 |
1 |
2018 |
| Drug |
sdregn2810/ipi |
1 |
2018 |
| Drug |
second-line chemotherapy |
1 |
2011 |
| Drug |
second-line chemotherapy agents |
1 |
2006 |
| Procedure |
segmentectomy |
1 |
2007 |
| Procedure |
segmentectomy/wedge resection |
1 |
2007 |
| Drug |
selenium |
1 |
2001 |
| Drug |
selumetinib 75 mg |
1 |
2012 |
| Drug |
selumetinib/docetaxel |
1 |
2014 |
| Drug |
sgn-15 |
1 |
2003 |
| Drug |
sgn-15, docetaxel |
1 |
2004 |
| Drug |
sgn-cd47m |
1 |
2019 |
| Drug |
sh-1028 |
1 |
2018 |
| Drug |
sh t00268c |
1 |
2005 |
| Device |
sham |
1 |
2018 |
| Other |
sham control |
1 |
2018 |
| Drug |
shark cartilage extract ae-941 |
1 |
2000 |
| Drug |
shenlingcao oral liquid |
1 |
2018 |
| Drug |
sid530, taxotere |
1 |
2009 |
| Drug |
sildenafil |
1 |
2008 |
| Drug |
simultaneous chemoradiotherapy for an luo |
1 |
2019 |
| Radiation |
single-fraction stereotactic body radiation therapy (sbrt) |
1 |
2009 |
| Drug |
single arm |
1 |
2019 |
| Drug |
sintilimab (approved) |
1 |
2019 |
| Drug |
sintilimab (m1b) |
1 |
2019 |
| Drug |
sintilimab/with docetaxel |
1 |
2019 |
| Drug |
sintilimab/with docetaxel monotherapy |
1 |
2019 |
| Drug |
sirolimus (rapamycin) |
1 |
2009 |
| Other |
skin biopsy |
1 |
2013 |
| Behavioral |
smoking cessation intervention |
1 |
2017 |
| Drug |
sns-595 injection |
1 |
2005 |
| Drug |
so-c101 |
1 |
2019 |
| Drug |
soblidotin |
1 |
2003 |
| Drug |
sonidegib |
1 |
2019 |
| Drug |
sorafenib (nexavar) |
1 |
2009 |
| Drug |
sorafenib / docetaxel/carboplatin |
1 |
2008 |
| Other |
spect-based treatment plan |
1 |
2012 |
| Diagnostic Test |
spect-ct scan |
1 |
2017 |
| Procedure |
spectroscopy |
1 |
2008 |
| Procedure |
spontaneous ventilation |
1 |
2018 |
| Drug |
ss1 (dsfv) pe38 |
1 |
2010 |
| Drug |
sta 4783 |
1 |
2004 |
| Drug |
sta 9090 |
1 |
2009 |
| Other |
staging of non-small cell lung carcinoma |
1 |
2016 |
| Combination Product |
standard chemoradiotherapy |
1 |
2018 |
| Radiation |
standard fractionation |
1 |
2016 |
| Drug |
standard maintenance for squamous nsclc |
1 |
2014 |
| Drug |
standard medical therapy |
1 |
2019 |
| Other |
standard palliative care group |
1 |
2009 |
| Drug |
standard platinum-based chemotherapy |
1 |
2007 |
| Radiation |
stereotactic ablative radiotherapy (sar) |
1 |
2017 |
| Radiation |
stereotactic body radiation therapy/surgery |
1 |
2014 |
| Radiation |
stereotactic body radiotherapy (sabr) |
1 |
2015 |
| Radiation |
stereotactic body radiotherapy (sbrt) 30 gy 3 fractions (#) |
1 |
2018 |
| Radiation |
stereotactic body radiotherapy (sbrt) 54 gy 3 fractions (#) |
1 |
2018 |
| Radiation |
stereotactic body radiotherapy (sbrt) dosed at the maximum tolerated dose |
1 |
2018 |
| Radiation |
stereotactic body radiotherapy/sbrt |
1 |
2019 |
| Radiation |
stereotactic radiation |
1 |
2010 |
| Radiation |
stereotactic radiation therapy (srt) |
1 |
2017 |
| Radiation |
stereotactic radiosurgery (srs) |
1 |
2018 |
| Radiation |
sterotactic body radiotherapy |
1 |
2019 |
| Radiation |
sterotactic body radiotherapy/sbrt |
1 |
2019 |
| Drug |
subcutaneous (sc) sea-cd40 |
1 |
2015 |
| Procedure |
sublobar resection |
1 |
2017 |
| Procedure |
subxiphoid uniportal vats |
1 |
2017 |
| Drug |
sulijia |
1 |
2017 |
| Drug |
sunitinib/rapamycin (drug will be held) |
1 |
2007 |
| Behavioral |
support education activity |
1 |
2018 |
| Procedure |
support group therapy |
1 |
2018 |
| Device |
surgeon’s ‘standard of care’ stapler |
1 |
2016 |
| Procedure |
surgical procedure |
1 |
1999 |
| Procedure |
surgical removal of primary and |
1 |
2019 |
| Procedure |
surgical removal of primary and/or of all oligometastases |
1 |
2019 |
| Procedure |
surgical resection - definitive local treatment. |
1 |
2019 |
| Procedure |
surgical resection of tumor |
1 |
2016 |
| Procedure |
surgical staging |
1 |
2007 |
| Other |
survivorship care plan |
1 |
2020 |
| Drug |
sutent |
1 |
2009 |
| Drug |
systemic therapy |
1 |
2019 |
| Drug |
systemic therapy/standard of care |
1 |
2019 |
| Drug |
tak-573 |
1 |
2019 |
| Drug |
tak-931 |
1 |
2017 |
| Drug |
talazoparib |
1 |
2019 |
| Drug |
talazoparib tosylate |
1 |
2019 |
| Drug |
talcum powder |
1 |
2019 |
| Drug |
tarceva (erlotinib hcl, osi-774 ) |
1 |
2002 |
| Drug |
tarceva (erlotinib hydrochloride) |
1 |
2009 |
| Drug |
tarceva (erlotinib) |
1 |
2006 |
| Drug |
targeted molecular therapy |
1 |
2016 |
| Drug |
targomirs |
1 |
2015 |
| Drug |
tarloxotinib bromide |
1 |
2019 |
| Drug |
tas-114 |
1 |
2016 |
| Drug |
taxane |
1 |
2015 |
| Drug |
taxoprexin |
1 |
2005 |
| Drug |
taxotereâ® |
1 |
2006 |
| Drug |
tc-210 t cells |
1 |
2019 |
| Biological |
tcr-t cells |
1 |
2018 |
| Biological |
tecemotide |
1 |
2009 |
| Radiation |
technetium-99 |
1 |
2004 |
| Radiation |
technetium 99m ethylenedicysteine-deoxyglucose |
1 |
2009 |
| Radiation |
technetium tc-99m albumin aggregated |
1 |
2016 |
| Radiation |
technetium tc-99m sulfur colloid |
1 |
2016 |
| Drug |
telaglenastat |
1 |
2019 |
| Drug |
telaglenastat hydrochloride |
1 |
2019 |
| Device |
telecoaching |
1 |
2019 |
| Other |
telehealth |
1 |
2020 |
| Behavioral |
telephone-based intervention |
1 |
2011 |
| Drug |
telisotuzumab vedotin |
1 |
2018 |
| Procedure |
temla |
1 |
2017 |
| Drug |
temoporfin |
1 |
2013 |
| Biological |
tergenpumatucel-l |
1 |
2015 |
| Drug |
tesevatinib |
1 |
2015 |
| Procedure |
testing for mutation status |
1 |
2010 |
| Drug |
tetrahydrouridine |
1 |
2016 |
| Drug |
tetrahydrouridine (thu) |
1 |
2017 |
| Drug |
tetrathiomolybdate |
1 |
2013 |
| Drug |
tew-7197 |
1 |
2018 |
| Drug |
tg01 |
1 |
2007 |
| Procedure |
therapeutic bronchoscopy |
1 |
2012 |
| Combination Product |
therapeutic lymphadenectomy (temla) |
1 |
2013 |
| Combination Product |
therapeutic lymphadenectomy (temla)/stereotactic body radiation therapy (sbrt) |
1 |
2013 |
| Radiation |
thoracic irradiation / pemetrexed |
1 |
2007 |
| Radiation |
thoracic radiation |
1 |
2017 |
| Radiation |
thoracic radiation therapy |
1 |
2019 |
| Radiation |
thoracic rt |
1 |
2019 |
| Radiation |
thoracic rt/durvalumab |
1 |
2019 |
| Procedure |
thoracotomy |
1 |
2015 |
| Radiation |
three-dimensional conformal radiation therapy |
1 |
2001 |
| Radiation |
three dimensional conformal radiotherapy |
1 |
2017 |
| Drug |
thymosin |
1 |
2018 |
| Drug |
tinzaparin sodium 100 ui |
1 |
2007 |
| Drug |
tinzaparin sodium 100 ui/kg/od for 12 weeks |
1 |
2007 |
| Drug |
tiragolumab |
1 |
2020 |
| Drug |
tislelizumab carboplatin nab-paxlitaxel |
1 |
2018 |
| Drug |
tislelizumab carboplatin paxlitaxel |
1 |
2018 |
| Drug |
tislelizumab,cisplatin |
1 |
2018 |
| Drug |
tislelizumab,cisplatin/carboplatin ,pemetrexed |
1 |
2018 |
| Other |
tissue oxygen measurement |
1 |
2014 |
| Drug |
tivantinib |
1 |
2010 |
| Drug |
tivozanib (av-951) |
1 |
2009 |
| Drug |
tlk286 (telcyta) hcl for injection |
1 |
2004 |
| Drug |
tlk286 in combination with docetaxel |
1 |
2002 |
| Drug |
tlk286, cisplatin |
1 |
2004 |
| Biological |
tn lymphocytes |
1 |
2015 |
| Drug |
tno155 |
1 |
2019 |
| Drug |
tocilizumab |
1 |
2017 |
| Procedure |
tomotherapy |
1 |
2005 |
| Drug |
topotecan/docetaxel combination |
1 |
2003 |
| Drug |
toripalimab injection (js001 ) combine with chemotherapy |
1 |
2019 |
| Drug |
toripalimab injection(js001 ) |
1 |
2019 |
| Dietary Supplement |
total aa vs eaa |
1 |
2010 |
| Dietary Supplement |
total aa vs eaa/leu |
1 |
2010 |
| Drug |
tpc -vinorelbine,gemcitabine,docetaxel, |
1 |
2011 |
| Drug |
tpc -vinorelbine,gemcitabine,docetaxel,/pemetrexed |
1 |
2011 |
| Drug |
tpx-0046 |
1 |
2019 |
| Drug |
tq-a3334 |
1 |
2020 |
| Drug |
tq-b3101 |
1 |
2019 |
| Drug |
tqb2450 |
1 |
2019 |
| Drug |
tqb3456 |
1 |
2018 |
| Drug |
trail-r1 mab (trm-1;hgs-etr1) |
1 |
2004 |
| Drug |
trail) |
1 |
2007 |
| Drug |
trametinib 0.5 mg |
1 |
2018 |
| Drug |
trametinib 1 mg |
1 |
2018 |
| Drug |
trametinib 1.5 mg |
1 |
2018 |
| Drug |
trametinib 2 mg |
1 |
2018 |
| Device |
transcutaneous vagus nerve stimulation |
1 |
2018 |
| Procedure |
transthoracic ultrasound |
1 |
2010 |
| Drug |
trastuzumab deruxtecan |
1 |
2017 |
| Procedure |
treatment by surgical resection |
1 |
2015 |
| Behavioral |
treatment of cancer quality of life questionnaire c30 |
1 |
2015 |
| Behavioral |
treatment of cancer quality of life questionnaire lc-13 |
1 |
2015 |
| Drug |
treprilumab combination with platinum-containing dual-drug chemotherapy |
1 |
2019 |
| Biological |
tricom vaccine |
1 |
2004 |
| Diagnostic Test |
truesight oncology 500 |
1 |
2019 |
| Drug |
ts-1 |
1 |
2013 |
| Drug |
ts-1/cisplatin |
1 |
2013 |
| Drug |
tsr-022 |
1 |
2017 |
| Drug |
tsr-042 |
1 |
2017 |
| Other |
tumor-infiltrating lymphocyte therapy |
1 |
2017 |
| Procedure |
tumor-infiltrating lymphocytes (til) |
1 |
2017 |
| Other |
tumor collection |
1 |
2019 |
| Procedure |
tumor specimen for methylation analysis |
1 |
2010 |
| Drug |
tvb-2640 |
1 |
2018 |
| Drug |
twice daily dosing as determined in phase 1 |
1 |
2020 |
| Drug |
ty-9591(10mg,40mg) qd. po |
1 |
2019 |
| Drug |
u3-1287 |
1 |
2010 |
| Drug |
u3-1402 |
1 |
2017 |
| Drug |
ucpvax |
1 |
2016 |
| Drug |
ufur |
1 |
2008 |
| Drug |
ufur/iressa |
1 |
2008 |
| Procedure |
ultrasound-guided transbronchial needle-delivered interstitial photodynamic therapy |
1 |
2018 |
| Procedure |
ultrasound imaging |
1 |
2008 |
| Procedure |
uniportal lobectomy with complete lymphadenectomy |
1 |
2019 |
| Other |
urine collection |
1 |
2019 |
| Other |
use of [18f]fdg - pet |
1 |
2016 |
| Other |
use of [18f]fdg - pet/ct for the diagnosis/staging of non-small cell lung carcinoma |
1 |
2016 |
| Behavioral |
usual care (routine chemotherapy cycles |
1 |
2013 |
| Behavioral |
usual care (routine chemotherapy cycles/imaging studies) |
1 |
2013 |
| Drug |
utidelone injection |
1 |
2018 |
| Biological |
uv1 synthetic peptide vaccine |
1 |
2013 |
| Biological |
uv1 synthetic peptide vaccine/gm-csf |
1 |
2013 |
| Device |
v |
1 |
2015 |
| Device |
v/q spect |
1 |
2015 |
| Biological |
v934-ep |
1 |
2008 |
| Biological |
v935 |
1 |
2008 |
| Biological |
v941 |
1 |
2019 |
| Biological |
vaccine |
1 |
2012 |
| Biological |
vaccine / polyiclc |
1 |
2012 |
| Drug |
val401 |
1 |
2016 |
| Drug |
valproic acid |
1 |
2004 |
| Drug |
vandetanib induction |
1 |
2008 |
| Drug |
vandetanib maintenance |
1 |
2008 |
| Drug |
vandetanib, selumetinib |
1 |
2012 |
| Drug |
varlilumab 3 mg |
1 |
2019 |
| Drug |
varlilumab 3 mg/kg |
1 |
2019 |
| Drug |
vatalanib |
1 |
2008 |
| Procedure |
vats |
1 |
2015 |
| Drug |
velcade/vorinostat |
1 |
2008 |
| Drug |
velcadeâ„¢ (bortezomib) for injection (formerly ps-341) |
1 |
2003 |
| Biological |
viagenpumatucel-l |
1 |
2015 |
| Device |
video-assisted thoracoscopic lobectomy with powered vascular stapler |
1 |
2017 |
| Procedure |
videothoracoscopy |
1 |
1999 |
| Device |
viewray mr-linear accelerator |
1 |
2019 |
| Biological |
vigilâ„¢ |
1 |
2010 |
| Drug |
vinblastine |
1 |
2010 |
| Drug |
vindesine |
1 |
1999 |
| Drug |
vinflunine |
1 |
2005 |
| Drug |
vinorelbine oral formulation |
1 |
2006 |
| Drug |
vinorelbine) |
1 |
2006 |
| Drug |
vinorelbine, cisplatin |
1 |
2017 |
| Drug |
vitamin a compound |
1 |
2019 |
| Drug |
volitinib |
1 |
2015 |
| Radiation |
volume modulated arc therapy |
1 |
2014 |
| Procedure |
vomiting therapy |
1 |
1999 |
| Biological |
vsv-ifnî²-nis |
1 |
2018 |
| Biological |
vv1 |
1 |
2020 |
| Drug |
vx-001 |
1 |
2013 |
| Drug |
vx-970 (m6620) |
1 |
2015 |
| Drug |
vx15 |
1 |
2017 |
| Drug |
vx15/2503 / avelumab |
1 |
2017 |
| Drug |
w |
1 |
2012 |
| Drug |
wbrt |
1 |
2013 |
| Procedure |
wedge resection |
1 |
2007 |
| Drug |
week |
1 |
2012 |
| Drug |
weekly - concomitant chemoradiation 2gy |
1 |
2012 |
| Drug |
weekly dp chemotherapy concurrent with thoracic radiotherapy |
1 |
2018 |
| Diagnostic Test |
whole body 18f-fdg pet |
1 |
2018 |
| Diagnostic Test |
whole body 18f-fdg pet/ct |
1 |
2018 |
| Radiation |
whole brain radiation therapy |
1 |
2012 |
| Radiation |
whole brain radiation(wbi) |
1 |
2012 |
| Radiation |
whole brain radiotherapy |
1 |
2015 |
| Drug |
with albumin-bound paclitaxel |
1 |
2020 |
| Combination Product |
with bevacizumab |
1 |
2020 |
| Drug |
with cisplatin |
1 |
2013 |
| Drug |
with docetaxel |
1 |
2019 |
| Drug |
with docetaxel monotherapy |
1 |
2019 |
| Drug |
with egfr-tki |
1 |
2019 |
| Drug |
with erlotinib |
1 |
2014 |
| Drug |
with osimertinib |
1 |
2019 |
| Drug |
with pemetrexed |
1 |
2018 |
| Other |
with radiofrequency ablation |
1 |
2019 |
| Drug |
with s-1 capsules |
1 |
2017 |
| Biological |
with the as15 adjuvant system gsk2302032a |
1 |
2013 |
| Drug |
with vinorelbine |
1 |
2018 |
| Drug |
wx-0593 tablets |
1 |
2017 |
| Drug |
x-396 |
1 |
2018 |
| Drug |
x-396(ensartinib) |
1 |
2020 |
| Drug |
xl147 (sar245408) |
1 |
2008 |
| Drug |
xl184 |
1 |
2008 |
| Drug |
xl765 (sar245409) |
1 |
2008 |
| Biological |
xmab20717 |
1 |
2018 |
| Biological |
xmabâ®22841 |
1 |
2019 |
| Biological |
xmabâ®23104 |
1 |
2018 |
| Drug |
xmt-1001 |
1 |
2007 |
| Drug |
xmt-1522 |
1 |
2016 |
| Biological |
xmt-1592 |
1 |
2020 |
| Biological |
xofigo |
1 |
2014 |
| Drug |
yangyinfang |
1 |
2016 |
| Drug |
yh25448 240mg |
1 |
2018 |
| Drug |
yiqifang |
1 |
2016 |
| Drug |
yiqiyangyinfang |
1 |
2016 |
| Procedure |
yoga |
1 |
2019 |
| Biological |
young til |
1 |
2014 |
| Radiation |
yttrium y 90 anti-cea monoclonal antibody ct84.66 |
1 |
2008 |
| Drug |
zactima (zd6474) |
1 |
2007 |
| Drug |
zd1839 (iressa) |
1 |
2006 |
| Drug |
zd4054 |
1 |
2008 |
| Drug |
zd6474 (vandetanib) |
1 |
2006 |
| Drug |
zd6474 (vandetanib) 100mg |
1 |
2005 |
| Drug |
zd6474 (vandetanib) 200mg |
1 |
2005 |
| Drug |
zd6474 (vandetanib) 300mg |
1 |
2005 |
| Drug |
zd6474, vandetanib |
1 |
2008 |
| Drug |
zileuton |
1 |
2003 |
| Drug |
zk 222584 |
1 |
2005 |
| Drug |
zn-e4 |
1 |
2018 |
| Drug |
zoledronic acid 4 mg |
1 |
2005 |
| Drug |
zometa |
1 |
2008 |
| Radiation |
zr-89 labelled durvalumab pet |
1 |
2019 |
| Radiation |
zr-89 labelled durvalumab pet/ct |
1 |
2019 |